Date of Preparation: April 17, 2008 Department of Urology

Transcription

CURRICULUM VITAE
STEVEN A. KAPLAN, M.D.
Date of Preparation:
A.
April 17, 2008
BACKGROUN INFORMATION
Address:
B.
Department of Urology
Weill Cornell Medical College
F9 West, Box 261
525 East 68th Street
New York, NY 10065
T: (212) 746 - 4811
F: (212) 746 – 5329
EDUCATIONAL BACKGROUND
College:
1974-1978
Awarded: 1978
CUNY - Brooklyn College
Brooklyn, New York
BS - Biochemistry
Medical School:
1978-1982
Awarded: 1982
Mount Sinai School of Medicine
New York, New York
M.D.
C.
PROFESSIONAL POSITIONS AND EMPLOYMENT
POST GRADUATE TRAINING
Intern:
1982-1983
Department of Surgery
Mount Sinai Hospital
New York, New York
Resident:
1983-1984
Department of Surgery
New York, New York
Resident:
1984-1988
Squier Urologic Clinic
Columbia-Presbyterian Medical Center
New York, New York
AUA Scholar:
1988 – 1990
Neurourology and Urodynamics
College of Physicians & Surgeons
Columbia University
1
Academic positions
1988-1989
Instructor
College of Physicians and Surgeons
1990 - 1994
Assistant Professor
College of Physicians and Surgeons
1994 - 1995
Herbert Irving Assistant Professor of Urology
Columbia University
1995 - 1997
Herbert Irving Associate Professor of Urology
Columbia University
1996-
Vice Chairman
Columbia University
1997-1998
Professor of Urology
Columbia University
1998 - 2005
Given Foundation Professor of Urology
Columbia University
1998 - 2003
Administrator
Columbia University
2001 - 2005
Adjunct Professor of Urology
Weill Medical College of Cornell University
2005 -
Professor of Urology
Hospital positions
1988- 89
Assistant Urologist, Department of Urology
2
1990 - 95
Assistant Attending, Department of Urology
1990 - 2005
Attending, Department of Urology
Helen Hayes Hospital
West Haverstraw, New York
1990 - 2005
Director, Prostate Center
Squire Urologic Clinic
1993 - 2005
Director of Neurourology
Squire Urologic Clinic
1993 - 2005
Chief, Urology Service
West Haverstraw, New York
1995 - 1997
Associate Attending, Department of Urology
1997 - 2005
Attending, Department of Urology
Columbia - Presbyterian Medical Center
1998 - 2002
Administrator, Department of Urology
New York Presbyterian Hospital
2000 - 2005
Adjunct Attending
New York Presbyterian Hospital – Weill Cornell
2001 - 2005
Residency Program Director
Columbia University Medical Center
2003 - 2005
Co – Director, Center for Bladder and Prostate Health
Columbia University Medical Center
2005
Chief, Institute of Bladder and Prostate Health
2005 - present
Attending, New York Presbyterian Hospital
D.
1.
LICENSURE, BOARD CERTIFICATION, AND MALPRACTICE
Licensure
(Every doctor appointed to the Hospital staff, except interns and aliens in the US
via non-immigrant visas, must have a New York State license or a temporary
3
certificate in lieu of the license.)
a.
2.
b.
State
Date of issue Date of last registration
New York State
1983– 1
June, 2007
If no license:
(1)
Do you have a temporary certificate?
(2)
Have you passed the examination for foreign medical school graduates?
c.
DEA number: AK2440903
Board Certification
Full Name of Board: American Board of Urology
Certificate #
10266
Date 02/28/92
3.
Malpractice insurance
Do you have Malpractice Insurance? Yes
Name of Provider: MCIC
Premiums paid by: WCMC
E.
PROFESSIONAL MEMBERSHIPS
Title
Organization
Member
American Medical Association
Member
Diplomate of the National Board of Medical
Examiners
Member:
Society of Female Urology and Urodynamics
Member
Westchester Medical Society
Member
New York State Medical Society
Member
American Diabetes Association
Member
National Kidney Foundation
Member
International Continence Society
Diplomat
American Board of Urology
Member
American Urologic Association
Officer
American Urologic Association/New York Section
Member
American Association of Clinical Urologists
Member
New York Academy of Medicine
Member
Society of University Urologists
Member
Society for Basic Urologic Research
Chairman
Young Members Group of the New York Section
of the American Urologic Association
Member
Endourology Society
Member
Societe Urologie Internationale
Fellow
The American College of Surgeons
Dates Joined
1983
1990
1992
1990
1996
2000
1991
1992
1986
1986
2002
1993
2001
1992
1998 – 2007
1997
1998
1994
4
F.
HONORS AND AWARDS
New York State Regents Scholarship
New York City Science Honors Program
Dean's list (CUNY - Brooklyn College)
Dean's Scholarship Prize
Summa Caum Laude
AOA - Mount Sinai School of Medicine
Arthur Aufses Sr. Surgical Prize
Ralph Colp Prize for Surgical Journalism
AUA Essay Contest, 2nd prize in clinical investigation
American Federation of Urologic Disease Scholar
Herbert Irving Fellowship
AUA - EUA Travel Fellowship - 1st alternate
1st Prize Presentation at NY Section (AUA) Meeting
Saul Horowitz, Jr. Memorial Award
John K. Lattimer Urology Lifetime Award
Kidney and Urology Foundation
Top Doctors in America
Best Doctors in New York
1974
1974-1978
1974-1978
1978
1978
1981, 1982
1982
1986
1987, 1991
1988, 1989
1994-1997
1996
1996
1998
2003
1997, 1998, 1999, 2000,
2001, 2002, 2003, 2004,
2005, 2006, 2007
1997, 1998, 2001, 2005,
2006, 2007
G.
INSTITUTIONAL/HOSPITAL AFFILIATION
4.
Primary Hospital Affiliation:
New York Presbyterian Hospital
5.
Other Hospital Affiliations:
N/A
6.
Other Institutional Affiliations:
N/A
H.
EMPLOYMENT STATUS
1.
Name of Current Employer(s):
2.
Employment Status (choose one):
Full-time salaried at Cornell
I.
CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT
EFFORT
Teaching
Resident education (Grand Rounds, Mortality and Morbidity): 1990 - current
Resident Program Director in Urology (Columbia University): 2000 – 2005
Fellowship Director (Neurourology and Voiding Dysfunction: 1994 - current
Responsible to coordinate resident education with respect to male and female voiding
dysfunction benign prostate hyperplasia (BPH), urinary incontinence, reconstructive surgery
and prostatitis.
5
Have directed the training of 18 fellows between Columbia University and Weill Cornell
Medical College
Clinical care
1990 – current: Focus on Neurourology, voiding dysfunction in adults, and benign prostate
hyperplasia . Have directed the urodynamic laboratory at both Columbia University and Weill
Cornell Medical College.
Administrative
COMMITTEES AND APPOINTMENTS
1988-1994
1989-1990
1
Chairman, Patient Care Committee
The Presbyterian Hospital
Infection Disease Committee
1989 - 1993
Chairman, Quality Assurance
989 - 1993
Urology Representative
Continuing Medical Education
Columbia University
1993 - 1998
Urology Resident Education Committee
1993 - 2001
Faculty Council of Columbia University
1994 - 2001
Pharmacy & Therapeutics Committee Columbia - Presbyterian Medical
Center
1996 - 2003
Medicare Compliance Committee Columbia - Presbyterian Medical Center
1996 - 2003
Director Medicare Compliance
Columbia - Presbyterian Medical Center
2000 - present
Finance Committee, Columbia University Practice Plan
2001
Strategic Planning Committee, Columbia University
2003 - 2004
Columbia University – Practice plan task force
2004 - 2005
Peer review committee: Columbia University FPO
6
2005 – current:
Chief, Institute for Bladder and Prostate Health
Research
1983-
Transplant Resident
"Renal and small bowel allografts in the rat"
1986-
Flow cytometry
Columbia University
"Study of urologic oncology using flow
cytometry"
1988-90
Neurourology
Columbia University
"Parameters of detrusor contractility in an
in-vitro whole bladder model in the rabbit"
1990 - 1993
Neurourology
Columbia University
Neurotropin expression in diabetic and obstructed bladders"
1991- 1994
Neurourology
Columbia University
“Gene expression in obstructed rabbit/rat bladders"
1993 - 1996
Neurourology
Columbia University
“Gene product expression in spinal cord injured rat bladders”
1995 - 1997
Neurourology
Columbia University
“Alpha adrenergic expression in obstructed rat bladders”
1997 – 2005
Molecular biology
Columbia University
“Vascular growth factors in the bladder and prostate”
See J. Research Support for current research activities
Current Percent Effort (%)
Teaching
Clinical Care
Administration
Research
TOTAL:
10%
50%
5%
35%
100%
Does the activity involve WMC
students/researchers? (Yes/No)
No
7
J.
RESEARCH EXPERIENCE
GRANTS (> $12,600,000)
American Foundation of Urologic Disease Scholar 1988 – 89 ($50,000)
Paralyzed Veterans of America 1988-1989 ($27,550)
"Parameters of Detrusor Contractility"
Merck, Sharp and Dohme 1989-1990 ($118,000)
"Urodynamic parameters in patients on a 5-alpha reductase inhibitor (MK-906)"
Pfizer 1990 ($67,000)
"The effect of doxazosin on mild hypertension and BPH"
Miles 1990 ($36,500)
"Low dose, short course therapy using ciprofloxacin in uncomplicated UTI"
Advanced Surgical Intervention, Inc. 1990-91
"Prostatic stents in BPH" ($10,000)
Berlex, Inc. 1990 ($57,000)
"Atamestane in Patients with BPH"
Berlex, Inc. 1990 ($14,500)
"Long Term Usage of Atamestane in Patients with BPH"
Tecnomatix, Inc. 1990
"Transrectal thermal therapy in the management of men with mild to moderate symptoms of prostatism"
American Medical Systems, Inc. 1991 ($14,000)
"The use of the Wallstent in the management of BPH"
Merck Sharp and Dhome, 1992 ($134,000)
"Long Term Usage of Proscar in the Treatment of BPH"
Smith Kline Beecham, 1992 ($145,560)
"A Comparison of Three Dose Levels of SK&F 105657 versus Placebo in the Treatment of BPH"
Abbott Laboratories 1992 ($77,000)
"Evaluation of the Clinical Effectiveness and Cost Effectiveness of Terazosin vs. Placebo in
the Treatment of Patients with Symptomatic Benign Prostatic Hyperplasia"
NIH Grant RU01 DK 46418-01 ($2,750,012) 9/92 – 10/97
"Drug Therapy for BPH: Urodynamic Correlation
NIH GrantDK44689 (collaborator) ($1,567, 890)
"Urinary Bladder Function: A Molecular Approach
8
Roberts Pharmaceuticals, 1993 ($24,700)
The effects of midodrine on women with incontinence"
Schwarz Pharma, 1993 ($29,650)
A Double-Blind, Placebo-Controlled, Randomized, Two-Way Crossover, Multicenter Study Evaluating
Levsin-SL in Influencing Volume of Urine Loss in Incontinent Women"
Yamanouchi Pharmaceuticals, 1993 ($72,000)
"A Second Phase III Multicenter, Placebo-Controlled Study
of Two Dosages (0.4 mg qd and
0.8 mg qd) of modified release YM 617 in Patients with the Signs and symptoms of Benign Prostatic
Hyperplasia"
Merck Pharmaceuticals, 1993 (10,000)
"A Double-Blind, Placebo Controlled, Crossover Study of the Effect of Prazosin on Uroflow in Normal
Men"
Yamanouchi Pharmaceuticals, 1993 ($75,000)
"An open label study using either 0.4 or 0.8 mg of tamsulosin in men with benign prostatic hyperplasia"
SmithKline Beecham Pharmaceuticals, 1994 ($68,500)
"A two-year, open-label, multicenter study of oral epristeride 80mg once daily in the treatment of benign
prostatic hyperplasia"
Abbott Laboratories, 1994 ($112,350)
"The long term safety and efficacy of terazosin administered once daily for the treatment of symptomatic
benign prostatic hyperplasia: an extension of study M91-639R"
Pfizer Pharmaceuticals, 1994 ($35,000)
“Terazosin versus doxazosin in the management of men with BPH”
Cryomedical Science, 1994 ($100,000)
“Use of cryosurgery in BPH”
NIH Grant 1995 ($2,211,000)
2 UO1 DK46418 - 04
“Medical therapy for BPH: A 6 year study”
SmithKline Beecham, 1995 ($83,000)
“A 1 year study on the efficacy and safety of epristeride in the management of men with benign prostatic
hyperplasia”
Pfizer Research Laboratories, 1996 ($47,431)
“Alpha receptor subtype expression in a rat hypertrophy /hyperplasia model”
ACMI, 1996 ($25,000)
“Electrovaporization of the prostate in men with benign prostatic hyperplasia”
Urologix, Inc., 1996 ($40,000)
9
“Thermotherapy versus TURP in the management of bladder outlet obstruction”
ACMI, 1996 ($25,000)
“Vaporization versus TURP in the management of BPH”
Medtronics, 1997 ($50,000)
“Bladder pacemakers”
Synthelabo, 1997 ($47,500)
“Use of alfuzosin SR in BPH”
DICE Award, 1998 ($15,000)
“Concomitant doxazosin and Caverject in patients with erectile dysfunction”
Merck ($75,000)
"Transition zone measurements in Asian men"
Boehringer Ingelheim, 1998 ($137, 500)
“Tamsulosin versus terazosin for BPH”
Pharmacia / Upjohn 1999 ($56,000)
“Long acting Detrol for stress incontinence”
Pharmacia / Upjohn 1999 ($87,000)
“Detrol in men with BPH and detrusor instability”
Merck ($47,500) 1999
"Effect of an M-3 inhibitor in the treatment of urge incontinence"
Forrest Pharmaceuticals ($31,500) 2000
"Effect of LS - 4321 in urge incontinence
Merck ($27,500) 2000
"Vioxx in the management of chronic prostatitis"
Wellspring ($64,000) 2001
“The effect of dibenzyline in men with BPH”
NIH Grant (DK608004 – 01) 2001 ($2,350,000) 2003 - 2009
DK4641: P.I.
“Minimally invasive alternative therapies: Multiethnic and urodynamic variability”
% effort: 10
NIH Grant (DK ) 2002 ($2,145,678): P.I.: 2004 - 2011
“ Phytotherapeutic agents in men with BPH”
% effort: 10
Pharmacia ($43,550) 2002
“Detrol in men with urgency”
10
Pfizer (67,845) 2004
“Use of sertraline in patients with interstitial cystitis”
K.
EXTRAMURAL PROFESSIONAL RESPONSIBILITES
EDITORIAL RESPONSIBILITIES
Urology (Editorial Board)
Journal of Urology
Journal of Endourology
Urology: Index & Reviews (Editorial Board)
Grand Rounds Urology (Editorial Board)
Current Urology Reports (Editor - in - Chief)
Current Prostate Reports (Editor – in – Chief)
Current Bladder Reports (Editor – in – Chief)
Men’s Urologic Health (Editor – in – Chief)
Journal of Urology (Editorial Board)
British Journal of Medicine (Editorial Board)
British Journal of Urology (Editorial Board)
European Journal of Urology
Prescriber”s Letter / Pharmacist’s Letter Specialty Consultants Panel
Medical Review (Editorial Board)
Cornell Urology Men’s Health Report (Editor – in – Chief)
Committees and Appointments
1994 - 1996
New York Section American Urologic Association: Chairman, Young Members
Section
1994 - 1997
American Urologic Association Ad Hoc Committee on Research
1994 - 1997
American Urologic Association Young Members Committee
1995
World Health Organization Consultation Panel on BPH
1996
American Urologic Association BPH Guidelines Committee
1996 - 2000
American Urologic Association New Technology Committee
1996 - 1998
American Urologic Association Laser Technology Committee
1996
Ad Hoc Reviewer
NIDDK O’Brien Grant Committee
1997
Program Committee, American Urologic Association Annual Meeting
2000 - 2005
Executive Committee, New York Academy of Medicine
2000 – present
Program Leader: BPH, American Urologic Association Annual Meeting
11
2001 - 2005
Executive Committee, Society of Practitioners
2002 - 2006
AUA Education Council
2003
Chair, NIDDK Peer – review, Prostatitis RFA
2003 - 2007
AUA Nominating Committee
2004 -
American Foundation of Urologic Disease: Prostate Council
2004 -
World Health Organization Member on Prostate Disease
2006 -
AUA Prize Essay Committee
2006 - 2007
Chair, NIDDK Strategic Committee on Prostate Disease
L.
BIBLIOGRAPHY
Peer Reviewed Publications (Total 515)
1.
Kaplan SA: Double lumen Hickman catheters in long term dialysis. Kidney International, 19:47 51, 1983.
2.
Shanzer H, Kaplan S: Double lumen silicone rubber indwelling venous catheters. Archives of
Surgery, 121, 89-94, 1986.
3.
Kaplan SA, Shanzer H, Racelli D, et al: Orthotopic, segmental small bowel transplantation in the
rat. Mount Sinai Journal of Medicine, 53: 112-116, 1986.
4.
Benson MC, Kaplan SA, Olsson CA: Prostate cancer in men under the age of 45. Journal of
Urology, 137:888 - 890, 1987.
5.
Kaplan SA, Karp F, Benson MC: Use of a DNA index and mean channel number to identify
subtle degrees of aneuploidy. Cytometry, 45:37 - 44, 1987.
6.
Kaplan SA, Benson MC: Mean channel number versus modal channel number in flow cytometric
analysis. Journal of Urology, 139: 322 - 327, 1988.
7.
Kaplan SA, Blaivas JG: A practical approach to the diagnosis of urinary incontinence. Seminars
in Neurology 53:139-142, 1988
8.
Blaivas JG, Kaplan SA: Urological dysfunction in patients with multiple sclerosis. Seminars in
Neurology- 51: 325-230, 1988.
9.
Kaplan SA, Blaivas JG: Lower urinary tract manifestations in diabetes mellitus. Journal of
Diabetic Complications. 3:15 - 19, 1988
12
10.
Kaplan SA, Sawczuk IS, Olsson CA: Contemporary cystectomy versus preoperative
radiotherapy and cystectomy for invasive bladder cancer. Urology 38: 67 - 71, 1988.
11.
Kaplan SA, Brown WC, Blaivas JG: Parameters of detrusor contractility: Effects of hysteresis
and bladder volume in an in-vitro whole rabbit model. Surgical Forum 40: 665-666, 1989.
12.
Kaplan SA, Blaivas JG, Brown WC, Schuessler GB: Parameters of detrusor contractility: I: The
effect of bladder volume and outlet resistance on Qmax, power and work in an in-vitro whole
rabbit model. Neurourology Urodynamics 8(4):375-376, 1989.
13.
Kaplan SA, Brown WC, Chancellor MB, Schuessler GB, Blaivas JG: Parameters of detrusor
contractility: II: The effect of outlet resistance on the mechanical indices: power, work and Wf. J
Urol 143:354 - 357, 1990.
14.
Kaplan SA, Blaivas JG: Management of bladder problems of the MS patient. Journal of
Enterostomal Therapy, 13:16 - 20, 1990.
15.
Kaplan SA, Brown WC, Levin RM, Blaivas JG: Parameters of detrusor contractility: I: The effect
of hysteresis, electrical stimulation and bladder volume in an in-vitro whole rabbit model.
Neurourology and Urodynamics. 10:53 - 57, 1991.
16.
Chancellor MB, Blaivas JG, Kaplan SA, Axelrod S: Bladder outlet obstruction versus impaired
detrusor contractility: the role of uroflow. J. Urol, 145:810 - 814, 1991
17.
Kaplan SA, Chancellor MB, Blaivas JG: Bladder and sphincter behavior in patients with spinal
cord injury. J. Urol. 146:113 - 117, 1991.
18.
Koo HP, Buttyan R, Olsson CA and Kaplan SA: Genetic response of the rat bladder during the
onset of streptozotocin induced diabetic cystopathy. Surgical Forum, 42:36 - 41, 1991.
19.
Kaplan SA, Shabsigh R, Soldo KA and Olsson CA: Prostatic and Periprostatic Interstitial
Temperature Measurements During Transrectal Hyperthermia. J Urol, 147:1562 - 1565, 1992.
20.
Kaplan SA, Kohn I, Amis S, O'Toole K, Bixon R and Giella J: Renal angiomyolipoma
presenting as a retroperitoneal hemorrhage after thrombolytic therapy for acute myocardial
infarction. N.Y. State J. Med. 92 (5)17 - 20, 1992.
21.
Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH: Prostatic
specific antigen: Means of distinguishing benign prostatic hypertrophy and prostate cancer. J
Urol, 147(3):815 - 819, 1992.
22.
Kaplan SA, Benson MC: Arterio-venous malformation of the ureter. Urology, 40(5):450-2, 1992.
23.
Chancellor MB, Kaplan SA, Blaivas JG: A new method of measuring uroflow in the rat bladder.
Neurourology and Urodynamics. 11:(2) 123 - 129, 1992.
24.
Kaplan SA, Blaivas JG: Neurophysiology of storage and voiding function. Current Opinion in
Urology, 2(4):248-251, 1992.
13
25.
Te AE, Buttyan R, Koo HP, Olsson CA, Kaplan SA : Nerve growth factors in diabetic cystopathy
Neurourol & Urodynam 11:4:303-304. 1992.
26.
Chancellor MB, Kaplan SA, Blaivas JG: The cholinergic and purinergic components of detrusor
contractility in a whole rabbit bladder model. J Urol,148:906-909, 1992
27.
Koo HP, Buttyan R, Olsson CA, Shabsigh R and Kaplan SA: Early molecular changes associated
with streptozotocin-induced diabetic bladder hypertrophy in the rat. Urol Res 1993: 21 (6):37581.
28.
Kaplan SA, Shabsigh R, Soldo KA, Blaivas JG and Olsson CA: Applicator-urethral distance as a
predictor of response after transrectal thermal therapy. Br. J. Urol 72 (2): 195-200, 1993.
29.
Kaplan SA, Soldo KA, Olsson CA: Daytime versus nighttime dosing of the long acting alpha
blockers, terazosin and doxazosin. Urology 42:129 - 132, 1993.
30.
Walton GR, Kaplan SA : Urinary dysfunction in tropical spastic paraparesis: preliminary
urodynamic survey. J Urol. 150 (3): 930-2, 1993.
31.
Kaplan SA, Merrill DC, Benson RC, Jr, Fuselier HA, Moseley WG, Parra R: The titan intraprostatic stent: the early United States experience. J Urol, November, 150:1198- 201, 1993.
32.
Santarosa R, Colombel M, Kaplan SA, Monson F, Levin R, Buttyan R: Regression of the
hypertrophied rabbit bladder involves extensive apoptosis of cells in the urothelium and serosal
lamnia. Laboratory Investigation, 70:503 - 510, 1994.
33.
Kaplan SA, Koo HP: Benign prostatic hyperplasia. Compr Ther 19(1):21-4, 1993.
34.
Kaplan SA and Olsson CA: Microwave therapy in the management of men with BPH: current
status. J. Urol Nov; 150 (5) Pt 2): 1597-602, 1993.S
35.
Seaman EK, Jacobs BZ, Blaivas JG, Kaplan SA : Persistence or recurrence of symptoms after
TURP: A urodynamic assessment. J. Urol Sep: 152 (2) 935-7, 1994.
36.
Kaplan SA, Soldo KA and Olsson CA: Effect of dosing regimen on efficacy and safety of
doxazosin in normotensive men with symptomatic prostatism. Urol Sep 44(3):348:52, 1994.
37.
Te A, Buttyan R, Greene L, Kaplan SA, Koo HP, Olsson CA, Shabsigh R: Neurotrophins in the
rat penis I: A developmental study. J Urol 152 (6): 2167 -72, 1994.
38.
Kaplan SA, Te AE and Jacobs BZ: Urodynamic evidence of vesical neck obstruction in men
with "chronic non-bacterial" prostatitis and the therapeutic role of endoscopic incision of the
bladder neck. J. Urol 152 (6):2063-5, 1994.
39.
Oesterling JE, Kaplan SA, Epstein HB, DeFalco AF and the North American Experience with
the Urolume Endoprosthesis as a treatment for benign prostatic hyperplasia: Long term results.
Urology 44 (3): 353-62, 1994.
14
40.
Kaplan SA, Te AE, Blaivas JG: Urodynamic findings in diabetic cystopathy: Surprising results.
J. Urol. 153 (2):342-4, 1995.
41.
Goluboff E, Chang D, Olsson CA, Kaplan SA : Urodynamics and the etiology of post prostatectomy incontinence. J Urol 153 (3): 1034-7, 1995.
42.
Kaplan SA, Goluboff E, Soldo KA, Olsson CA, Dverka PD: Patient choice for symptomatic
prostatism. Urology, 45:398, 1995.
43.
Kaplan SA, Soldo KA, Olsson CA: Terazosin and doxazosin in normotensive men with
symptomatic prostatism: effect of dosing regimen on efficacy and safety. Euro Urol 28 (3) 223-8,
1995.
44.
Kaplan SA, Chiou RK, Morton WJ, Katz PG and The North American TITAN Stent study group.
Urology 45 (2):234-40, 1995.
45.
Kaplan SA, Goluboff ET, Olsson CA, Deverka PA. Chmiel JJ: Effect of demographic factors,
urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign
prostatic hyperplasia. Urol 45 (3) :398-405, 1995.
46.
Goluboff E, Kaplan SA, Fisch HF: Seminal Vesicle Urinary Reflux as a Complication of
Transurethral Resection of the Ejaculatory Ducts. J. Urol 153 (4) 1223-5, 1995.
47.
Kaplan SA, Greenberg R, Baust J: A comparative assessment of cryosurgical devices: application
to prostatic disease. Urol 1995 45 (4): 692-9, 1995.
48.
Kaplan SA and Te AE: Uroflowmetry and Multichannel Urodynamics. Urol Clin N Amer 22
(2): 309-20, 1995.
49.
Te AE and Kaplan SA: Transurethral electrovaporization of the prostate (TVP): A novel method
of treating men with benign prostatic hyperplasia. Urol 45 (4):566-72, 1995.
50.
Brisman JL, Kirsch AJ, Taylor JA, Birch BD, Hibshoosh HH and Kaplan SA : Pulmonary
lmphangiomyomatosis in tuberous sclerosis: association with chronic renal failure: Case report
and review of the literature. P & S Med Rev, 2:17, 1994.
51.
Kaplan SA, and Te AE: Transurethral electrovaporization of the prostate (TVP): An
electrosurgical modification of TURP. Curr Surg Techn 8 (1): 1-8, 1995.
52.
Kaplan SA, and Te AE: A comparative study of transurethral resection of the prostate using a
modified electrovaporizing loop and transurethral laser vaporization of the prostate. J Urol 154
(5): 1785-90, 1995.
53.
Kaplan SA, Te AE, Pressler LB and Olsson CA: Transition zone index (TZI), a novel method of
assessing benign prostatic hyperplasia: correlation with symptoms, uroflow and detrusor pressure.
J Urol 154 (5): 1764-9, 1995.
15
54.
Kaplan SA, Meade - D’alisera P, Quinones S and Soldo K: Doxazosin in physiologically and
pharmacologically normotensive men with benign prostatic hyperplasia: a study of safety and
efficacy. Urol 46 (4) 512-7, 1995.
55.
Kaplan SA, Bowers DL, Te AE and Olsson CA: The differential diagnosis of prostatism: a 12
year retrospective analysis of symptoms, urodynamics and satisfaction this therapy. J Urol 155
(4):1305-8, 1996.
56.
Roehrborn C, Oesterling JE, Auerbach S, Kaplan SA, and the HYCAT Study Group:
Effectiveness and safety of terazosin versus placebo in the treatment of men with symptomatic
benign prostatic hyperplasia in the HYCAT study. Urology 47 (2): 159-68, 1996.
57.
Kaplan SA and Olsson CA: Patient satisfaction with finasteride for the treatment of symptomatic
benign prostatic hyperplasia. Clin Ther 18 (1): 73-83, 1996.
58.
Te AE and Kaplan SA: Electrovaporization of the prostate. Current Opinion in Urology. 6(1) 3 9, 1996.
59.
Kaplan SA, Olsson CA, Te AE: The AHCPR guidelines in the evaluation of men with lower
urinary tract symptoms: at 2 years follow - up, does it work? J Urol 155(6): 1971-4, 1996.
60.
Kaplan SA: Doxazosin in the elderly male patient with hypertension and BPH. Eur Urol. 29:
178 - 181, 1996.
61.
Kaplan SA, Ikeguchi EF, Santarosa RP, D’Alisera PM, Hendricks J, Te AE and Miller M:
Etiology of voiding dysfunction in men < 50 years of age. Urol 47 (6): 836-9, 1996.
62.
Reis RB and Kaplan SA : Significant correlation of the AUA symptom score and a novel
urodynamic parameter: detrusor contraction duration. J Urol. 156:1668 - 1672, 1996.
63.
Kaplan SA and Santarosa RP, Te AE: Comparison of fascial and vaginal wall slings in the
management of intrinsic sphincter deficiency. Urol 47 (6): 885-9, 1996.
64.
Te AE, Santarosa R, Kaplan SA: Electrovaporization of the prostate: an electrosurgical
modification of the standard TURP in 93 patients with BPH. J Endourol 10: 65 - 69, 1996.
65.
Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, Ice K, Dias N, for the
Multicenter Study Group: Doxazosin in benign prostatic hyperplasia: long term efficacy and safety
in hypertensive and normotensive patients. J. Urol 57 (2):525-30, 1997.
66.
Santarosa RP and Kaplan SA: Stress urinary incontinence in women. Brazilian J Urol 13:329 337, 1996.
67.
Kaplan SA and Kaplan NM: Alpha blockade as a monotherapy for both hypertension and BPH.
Urol 48 (4): 541-50, 1996.
16
68.
McKiernan J, Kaplan SA, Te AE, Santarosa RP and Sawczuk IS: Transurethral
electrovaporization of bladder tumors. Urol 48 (2):207-10, 1996.
69.
Kaplan SA: BPH: Are we too hot for new therapies? J Urol 156 (2 Pt 1):426-7, 1996.
70.
Kaplan SA, Santarosa RP and Te AE: Transurethral electrovaporization of the prostate: one year
experience. Urol 48 (6):876-81., 1996.
71.
Kaplan SA: Electrovaporization of the prostate: durable modality or passing fad? Urol 49 (2):
157-9, 1997.
72.
Klein LT and Kaplan SA: Prostatic stents for benign prostatic hyperplasia. J Long Term
Complications of Med Implants. J Long Term Compl 7(1): 101- 114, 1997.
73.
Kaplan SA, Santarosa RP, D’Alisera PM, Fay BJ, Ikeguchi EF, Hendricks J, Klein L, Te AE:
“Pseudo” dyssynergia (contraction of the external sphincter during voiding) misdiagnosed as
“chronic non - bacterial prostatitis” and the role of biofeedback as a therapeutic option. J Urol.
157:897 - 901, 1997.
74.
Kaplan SA, Meade D’Alisera P: Tolerability of alpha blockade with doxazosin as a therapeutic
option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of
seven double - blind placebo - controlled studies. Am J Ger 53A(3):M201 – M206, 1998.
75.
Kaplan SA, Te AE, Ikeguchi E, Santarosa RP: Safety and efficacy of alpha blockers in the
treatment of men over the age of 80 with benign prostatic hyperplasia. British Journal of Urology.
1999
76.
Mobley D, Kaplan SA, Ice K, Gaffney and Dias N: Effect of doxazosin on the symptoms of
benign prostatic hyperplasia: results from three double - blind placebo - controlled studies. Int J
Clin Prac. 51(5), 1997.
77.
Sandler P, Avillo C, Kaplan SA: Detrusor areflexia in a patient with myasthenia gravis. Int J
Urol. 5(2): 188 – 190, 1998.
78.
Kaplan SA, Laor E, Fatal M, Te AE: Transurethral resection of the prostate (TURP) versus
transurethral electrovaporization of the prostate (TVP): a blinded, prospective comparative study
with 1 year follow - up. J. Urol. February, 1998.
79.
Kaplan SA, Kohn IJ, Te AE and Reis RB: Intermittent alpha blocker therapy in the treatment
of men with lower urinary tract symptoms. Urology, 52:1, 1998.
80.
Shabsigh R, Klein L, Seidman S, Kaplan SA, Lehroff B, Ritter J: Increased incidence of
depressive symptoms in men with erectile dysfunction. Urology, 52(5): 848 – 852, 1998.
81.
Kaplan SA: Minimally invasive alternative therapeutic options for lower urinary tract
symptoms. Urology, 51(4A): 32, 1998.
17
82.
Kaplan SA, Reis RB, Kohn IJ, Shabsigh R, Te AE: Combination Therapy utilizing oral alpha
blockers and intracavernosal injection in men with erectile dysfunction. Urology, 52(5): 739,
1998.
83.
Reis RB, Te AE, Cologna AJ, Suaid HJ, and Kaplan SA: Interstitial thermometry in men
undergoing electrovaporization of the prostate. J Endourol, 13 (1):53 - 6, 1999.
84.
Kaplan SA, Staiman VB, Jacobs BZ, Reis B, Te AE: The ratio of transition zone volume to
total prostate volume is higher in African - American men than in their Hispanic or Caucasian
counterparts. British Journal Urology, February, 1999.
85.
Kaplan SA: Alternative instrumental treatments in BPH electrosurgery. Eur Urol, February,
1999.
86.
Weiner DM, Kaplan SA: Electrosurgery using the Vaportorde. Eur Urol 35(2): 166 – 72,
1999.
87.
Kaplan SA, Reis RB, Kohn IJ, Ikeguchi EF, Laor E, Te AE: Safety and efficacy of sildenafil in
women with sexual dysfunction. Urology, March, 1999.
88.
Roehrborn C, Kaplan SA, Waldstreicher J: Serum prostate specific antigen concentration is a
powerful predictor of acute urinary retention and need for surgery in men with clinical benign
prostatic hyperplasia. Urology, March, 1999.
89.
Kaplan SA: Uroselective alpha blockade for BPH: Clinical reality or marketing savvy? Urology,
54(5): 776 – 9, 1999.
90.
Hayek OR, Shabsigh A, Kaplan SA et al: Castration induces acute vasoconstriction of blood
vessels in the rat prostate concomitant with a rapid reduction of blood flow. J Urol., 162
(4):1527-31, 1999.
91.
Kaplan N, Kaplan SA, Quinn S, Grossman EB: Doxazosin mesylate for the treatment of
concomitant hypertension and benign prostatic hyperplasia: an open label study in patients with
well – controlled hypertension. Am J. Med. October, 1999.
92.
Kaplan SA, Garvin D, Gilhooley P, Koppel M, Labasky R, Milstein R, Reddy P, Rosenberg S,
Sussman D, White C, Lee M, Pappas F and Waldstreicher J for the PLESS Study Group. The
impact of baseline symptom severity on future risk of BPH – related outcomes and long – term
response to finasteride. Urology, July 2000.
93.
Shabsigh A, Hayek OR, Weiner D, Saidi J, Kaplan SA, Kiss A, Burchardt M, Buttyan R, Levin
RM: Acute increase in blood flow to the rat bladder subsequent to partial bladder outlet
obstruction. Neurourol Urodynam, 19:195-206, 2000.
94.
Kaplan SA, Stifelman M, Avillo C, Reis RB and Te AE: Detrusor contraction duration (DCD)
may predict response to alpha blocker therapy for lower urinary tract symptoms. Eur Urol, 37
(3):314-317, 2000.
18
95.
Kaplan SA, Te AE, Young GHP, Andrade A, Cabelin MA and Ikeguchi EF: Prospective analysis
of 373 consecutive women with stress urinary incontinence treated with a vaginal wall sling: the
Columbia and Cornell University. J Urol, 164:1623 – 1627, 2000.
96.
Shabsigh A, Ghafar MA, De la Taille A, Burchardt M, Kaplan SA, Anastasiadis AG, Buttyan
R: Biomarker analysis demonstrates hypoxic environment in the castrated rat ventral prostate
gland. J Cell Biochem, 81:437-444, 2001.
97.
Kaplan SA, Holtgrewe HL, Bruskewitz R, et al: Comparison of the efficacy and safety of
finasteride in older versus younger men with benign prostatic hyperplasia. Urology, 57(6):
1073 – 7, 2001.
98.
Kaplan SA: 5 – alpha reductase inhibitors: what role should they play? Urology, 58: 65 – 70,
2001.
99.
Choi J, Ikeguchi EF, Lee SW, Choi HY, Te AE, Kaplan SA: The high prevalence of benign
prostatic hyperplasia related urinary tract symptoms in Korean men is due to a high transition
zone index. Eur. Urol., 42 (1): 7 - 11, 2002.
100. Kruzer E and Kaplan SA: Cost effectiveness model comparing trimethoprim sulfamethoxazole
and ciprofloxacin for the treatment of chronic bacterial prostatitis. European Urology, 42: 163 –
166, 2002.
101. Ghafar MA, Anastasiadis AG, Olsson LE, Chichester P, Kaplan SA, Buttyan R, Levin RM :
Hypoxia and an angiogenic response in the partially obstructed rat bladder. Laboratory
Investigation, 82(7): 903 – 909, 2002.
102. Kaplan SA: Increased bladder apoptosis with alpha – 1 adrenoreceptor antagonists in benign
prostatic hyperplasia. J Urol 169 (4), 1623, 2003.
103. Kaplan SA: Quantitative evaluation of prostatectomy for benign prostatic hypertrophy under a
national health insurance law: a multi-centre study.
J Urol. 2003 Apr;169(4):1622.
104. Kaplan SA: Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and 1D
adrenergic receptor antagonists, on bladder activity in rats.
J Urol 2003, 169 (4): 1621.
105. Kaplan SA: Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic
hyperplasia and prostatic cancer. J Urol 2003, 169(4):1621.
106. Kaplan SA: The value of power Doppler imaging to predict the histologic components of
benign prostatic hyperplasia. J Urol 2003, 169 (4): 1620.
107. Kaplan SA: Boosted decision tree analysis of surface-enhanced laser desorption/ionization
mass spectral serum profiles discriminates prostate cancer from noncancer patients. J Urol.
2003 Apr;169(4):1620.
19
108. Kaplan SA: Association of polymorphisms within androgen receptor, 5 - alpha - reductase and
PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. J
Urol. 2003, Apr;169(4):1619.
109. Kaplan SA: Office-based transurethral microwave thermotherapy using TherMatrx TMx2000. J Urol. 2003 Apr;169(4):1618-9.
110. Kaplan SA, Ghafar MA, Lam JS, Fromer D, Te AE: Use of finasteride as a diagnostic tool in
evaluating men with a serum PSA > 4 and previous negative prostate biopsy. Urology, 60 (3): 464
– 468, 2002.
111. Kaplan SA: Soy isoflavonoid equol modulates the growth of benign and malignant prostate
epithelial cells in vitro. J Urol 170 (1): 339 – 340, 2003.
112. Kaplan SA: Saw palmetto alters nuclear measurements reflecting DNA content in men with
symptomatic BPH: evidence for a possible molecular mechanism. J Urol 170 (1): 340, 2003.
113. Kaplan SA: Long term (7 – 8 year) experience with finasteride in men with benign prostatic
hyperplasia. J Urol 170 (1): 341, 2003.
114. Kaplan SA: Holmium laser enucleation for large (greater than 100 ml) prostate glands. J Urol
170 (1): 341 - 342, 2003.
115.
Kaplan SA: Sexual function in patients treated for benign prostatic hyperplasia reflecting DNA
content in men with symptomatic BPH: evidence for a possible molecular mechanism. J Urol
170 (1): 342, 2003.
116.
Kaplan SA: Transurethral interstitial laser coagulation of the prostate and transurethral
microwave thermotherapy vs. transurethral resection or incision of the prostate: results of a
randomized controlled study in patients with symptomatic benign prostatic hyperplasia. J Urol
170 (1):342 - 343, 2003.
117.
Kaplan SA: Serum human glandular kallikrein (hK2) and insulin – like growth factor 1 (IGF –
1) improve the discrimination between prostate cancer and benign prostate hyperplasia in
combination with total and % free PSA. J Urol 170 (1): 343, 2003.
118.
Kaplan SA: Effect of catheter size on urodynamic assessment of bladder outlet obstruction. J
Urol 170 (1): 344, 2003.
119.
Bautista OM, Kusek JW, Nyberg LM, McConnell JD, Bain R, Miller G, Crawford ED, Kaplan
SA, Sihelnik SA, Brawer MK, Lepor H for the MTOPS Research Group. Controlled Clinical
Trials, 24 (2): 224 – 43, 2003.
120.
McConnell JD………..Kaplan SA, et al : The long term effect of doxazosin, finasteride and
combination therapy on clinical progression of lower urinary tract symptoms and benign
prostatic hyperplasia in the Medical Therapy of Prostatic Symptoms (MTOPS) trial. NEJM,
December, 2003.
20
121.
Kaplan SA: Expression of Colony – stimulating factor 1 receptor during prostate development
and prostate cancer progression. J Urol. 170(4): 1475 – 1476, 2003.
122.
Kaplan SA: Normal, benign, preneoplastic, and malignant prostate cells have distinct protein
expression profiles resolved by surface enhanced laser desorption / ionization mass
spectrometry. J Urol. 170 (4):1476, 2003.
123.
Kaplan SA: Differentiation of prostate cancer from benign prostate hypertrophy using dual –
echo dynamic contrast MR imaging. J Urol. 170 (4): 1476, 2003.
124.
Kaplan SA: A randomized, double – blind crossover study of tamsulosin and controlled –
release doxazosin in patients with benign prostatic hyperplasia. J Urol. 170 (4): 1477, 2003.
125.
Kaplan SA: Medical Therapy for Asymptomatic Men with BPH: Primum Non Nocere.
Urology, 62(5):784 – 785, 2003.
126.
Kaplan SA: Heat versus drugs in the treatment of benign prostatic hyperplasia. J Urol. 170
(4): 1477 – 1478, 2003.
127.
Kaplan SA: Rotoresect for bloodless transurethral resection of the prostate: a 4 – year follow –
up. J Urol. 170 (4): 1478, 2003.
128.
Kaplan SA: Benign prostate – specific antigen (BPSA) in serum is increased in benign prostate
disease. J Urol. 170 (4): 1478 – 1479, 2003.
129.
Landis JR, Kaplan SA, Swift S: Impact of incontinence severity of antimuscarinic therapy in
patients with overactive bladder. J Urol, 171(1):752 – 757, 2004.
130.
Weissman MM, Gross R, Fryer A, Heiman GA, Gameroff MJ, Hodge SE, Kaufman D,
Kaplan SA: Interstitial cystitis and panic disorder: a potential genetic syndrome. Archives of
General Psychiatry. 61: 273 – 279, 2004.
131.
Kaplan SA, Volpe M, Te AE: A prospective one – year trial using saw palmetto versus
finasteride in the treatment of category III prostatitis / chronic pelvic pain syndrome. J Urol,
171:345 – 349, 2004.
132.
Kaplan SA: Cholinergic innervation and function in the prostate gland. J Urol, 171(1): 538,
2004.
133.
Kaplan SA: Early treatment of benign prostatic hyperplasia: implications for reducing the risk
of permanent bladder damage. J Urol, 171(1):538 – 539, 2004.
134.
Kaplan SA: Incidence and prevalence of lower urinary tract symptoms suggestive of benign
prostatic hyperplasia in primary care – The Triumph Project. J Urol,171(1): 539 – 540, 2004.
135.
Kaplan SA: 5 – year outcome of a prospective randomized trial to compare transurethral
electrovaporization of the prostate and standard transurethral resection. J Urol, 171(1): 540,
2004.
21
136.
Kaplan SA: A 4 – year follow – up of a randomized prospective study comparing transurethral
electrovaporization of the prostate with neodymium:Yag laser therapy for treating benign
prostatic hyperplasia. J Urol, 171(1): 540, 2004.
137.
Kaplan SA: Cooled thermotherapy for the treatment of benign prostatic hyperplasia: durability
of results obtained with the Targis system. J Urol, 171(1): 541 – 542, 2004.
138.
Kaplan SA: Minimal transurethral prostatectomy plus bladder neck incision versus standard
transurethral prostatectomy in patients with benign prostatic hyperplasia: A randomized
prospective study. J Urol, 171(1): 542, 2004.
139.
Kaplan SA: Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on
rabbit isolated corpus cavernosum. J Urol, 171(1):542 – 543, 2004.
140.
Kaplan SA: Insulin – like growth factor I, insulin – like growth factor binding protein 3, and
urologic measures of benign prostatic hyperplasia. J Urol, 171(1):543, 2004.
141.
Kaplan SA: Apoptotic and proliferative index after alpha – 1 – adrenoreceptor antagonist and /
or finasteride treatment in benign prostatic hyperplasia. J Urol, 171(1):543 – 544, 2004.
142.
Kaplan SA: Percent – free prostate specific antigen is elevated in men on hemodialysis or
peritoneal dialysis treatment. J Urol, 171(1):544, 2004.
143.
Kaplan SA: Prostate cancer versus hyperplasia: relationships with prostatic and adipose tissue
fatty acid composition. J Urol, 171(1):538, 2004.
144.
Kaplan SA: BPH management: statistical significance may not translate into clinical relevance.
J Urol, 171:1207 – 1208, 2004.
145.
Kaplan SA: Use and misuse of the concept of quality of life in evaluating surgical treatments
for lower urinary tract symptoms. J Urol 171(4): 1751 – 1752, 2004.
146.
Kaplan SA: Identification of baseline clinical factors which predict medical treatment failure
of benign prostatic hyperplasia: an observational cohort study. J Urol 171(4): 1752, 2004.
147.
Kaplan SA: Long term evaluation of transurethral needle ablation of the prostate (TUNA) for
treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from
three centers. J Urol 171(4):1752 - 1753,
2004.
148.
Kaplan SA: Increased discrimination between benign prostatic hyperplasia and prostate cancer
with equimolar total prostate specific antigen measurement. J Urol 171(4): 1753 – 1754, 2004.
149.
Kaplan SA: Benign growth of different prostate zones in aging men with slightly elevated PSA
in whom prostate cancer has been excluded: aprospective study of 510 patients. J Urol
171(4):1754, 2004.
22
150.
Kaplan SA: Prostatic epithelial and luminal area in the transition zone acini: morphometric
analysis in normal and hyperplastic human prostate. J Urol 171(4): 1754 – 1755, 2004.
151.
Kaplan SA: Holmium laser enucleation of the prostate: morbidity in a series of 206 patients. J
Urol 171(4): 1755, 2004.
152.
Sandhu JS, Ng C, Egan C, Kaplan SA, Te AE: High-power potassium-titanyl- phosphate
(KTP) photoselective laser vaporization of the prostate (PVP) for the treatment of benign
prostatic hyperplasia (BPH) in men with large prostates. Urology, 64:1155 – 1159, 2004.
153.
Kaplan SA: Use of alpha adrenergic inhibitors in the treatment of benign prostatic hyperplasia.
Urology, 63(3): 428 - 435.
154.
Walmsley K and Kaplan SA: Transurethral microwave thermotherapy (TUMT) for benign
prostate hyperplasia (BPH) - Separating truth from marketing hype. J Urol, 172(4): 1249 –
1255, 2004.
155.
Kaplan SA: The long – term effect of doxazosin, finasteride, and combination therapy on the
clinical progression of benign prostatic hyperplasia. J Urol, 172(1): 413 – 414, 2004.
156.
Kaplan SA: Use of α – blockers and the risk of hip / femur fractures. J Urol, 172(1): 414,
2004.
157.
Kaplan SA: First dose efficacy of alfuzosin once daily in men with symptomatic benign
prostatic hyperplasia. J Urol, 172(1): 415, 2004.
158.
Kaplan SA: Phytomedicines for the prostate: J Urol, 172(1):415, 2004.
159.
Kaplan SA: The association between lower urinary tract symptoms and erectile dysfunction in
four centres: the UrEpik study. J Urol, 172(1):416, 2004.
160.
Kaplan SA: Variations of transition zone volume and transition zone index after transurethral
needle ablation for symptomatic benign prostatic hyperplasia. J Urol, 172(1): 416 – 417, 2004.
161.
Kaplan SA: The effect of urethral instrumentation on uroflowmetry. J Urol,172(1):417 – 418,
2004.
162.
Kaplan SA: Nd:YAG laser ablation plus transurethral resection for large prostates in high –
risk patients. J Urol, 172(1):418, 2004.
163.
Kaplan SA: Transurethral resection vs microwave thermotherapy of the prostate: a cost –
consequence analysis. J Urol, 172(1):418 – 419, 2004.
164.
Kaplan SA: Expression of Protein C Inhibitor (PCI) in benign and malignant prostatic tissues.
J Urol, 172(1): 419, 204.
165.
Kaplan SA: The usefulness of serum human kallikrein 11 for discriminating between prostate
cancer and benign prostatic hyperplasia. J Urol, 172(1): 419 – 420, 2004.
23
166.
Kaplan SA: Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary
disturbances caused by benign prostatic hyperplasia: A comparative, randomized, two – drug
crossover study. J Urol, 172(4):1575, 2004.
167.
Kaplan SA: Metabolic profile in patients with benign prostate hyperplasia or prostate cancer
and normal glucose tolerance. J Urol, 172(4): 1575 – 1576, 2004.
168.
Kaplan SA: Comparative efficacy of two α1 - adrenoreceptor antagonists, doxazosin and
alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement” J
Urol, 172(4): 1576 – 1577, 2004.
169.
Kaplan SA: Lower urinary tract symptoms and male sexual dysfunction: the multinational
survey of the aging male (MSAM – 7). J Urol, 172(4):1577, 2004.
170.
Kaplan SA: Management of acute urinary retention secondary to benign prostatic hyperplasia
in the UK: a national survey. J Urol, 172(4): 1577 – 1578,
2004.
171.
Kaplan SA: Expression of vascular endothelial growth factor receptor – 3 (VEGFR – 3) in
human prostate. J Urol, 172(4): 1578, 2004.
172.
Kaplan SA: Functional and anatomical effects of hormonally induced experimental prostate
growth: a urodynamic model of benign prostatic hyperplasia (BPH) in the beagle. J Urol,
172(4): 1579, 2004.
173.
Kaplan SA: Androgen receptor gene polymorphism and increased risk of urologic measures of
benign prostatic hyperplasia. J Urol, 172(4): 1579 – 1580, 2004.
174.
Kaplan SA: Intra – individual variation of serum prostate specific antigen levels in men with
benign prostate biopsies. J Urol, 172(4): 1580, 2004.
175.
Kaplan SA: Management of inguinal hernia with benign prostatic hyperplasia: simultaneous
inguinal hernioplasty with transurethral resection of the prostate. J Urol, 173: 514, 2005.
176.
Kaplan SA: Marked suppression of dihydrotestosterone in men with benign prostatic
hyperplasia by dutasteride, a dual 5α – reductase inhibitor. J Urol, 173: 514 - 515, 2005.
177.
Kaplan SA: Efficacy and safety of dutasteride in the four – year treatment of men with benign
prostatic hyperplasia. J Urol, 173: 515, 2005.
178.
Kaplan SA: Modeling of the pH – and the temperature – dependent deviations of the free to
total PSA (prostate specific antigen) ratios for clinical predictability of prostate cancer and
benign prostate hyperplasia. J Urol, 173(4): 1266, 2005.
179.
Kaplan SA: Updated meta- analysis of clinical trial of Serenoa repens extract in the treatment
of symptomatic benign prostatic hyperplasia. J Urol, J Urol 173: 516, 2005.
24
180.
Kaplan SA: Apoptosis incidence and protein expression of p53, TGF – α receptor II, p27 kip 1 ,
and Smad4 in benign, premalignant and malignant human prostate. J Urol, 173(3): 912 – 913,
2005.
181.
Kaplan SA: Interleukin – 8 expression is increased in senescent prostatic epithelial cells and
promotes the development of benign prostatic hyperplasia. J Urol, 173(3): 913, 2005.
182.
Kaplan SA: Reduction of rat prostate weight by combined quercetin finasteride treatment is
associated with cell cycle deregulation. J Urol, 173(3): 914, 2005. in press.
183.
Kaplan SA: Prostate – specific antigen in the assessment of organ donors. J Urol, 173(1): 161,
2005.
184.
Kaplan SA: Analysis of the inflammatory network in benign prostate hyperplasia and prostate
cancer. J Urol, 173(1): 161, 2005.
185.
Kaplan SA: The relation of lower urinary tract symptoms with life style factors and objective
measures of benign prostatic enlargement and obstruction: An Italian survey. J. Urol,
173(6):2058, 2005.
186.
Kaplan SA: Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH
patients – PERMAL study subset analysis. J Urol, 173(5):1667 - 1668, 2005.
187.
Kaplan SA: The role of lipido – sterolic extract of Serenoa repens in the management of
lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol, 173(5):1667,
2005.
188.
Kaplan SA: Lycopene: modes of action to promote prostate health. J Urol, 173(5): 1667,
2005.
189.
Kaplan SA: Optimizing the medical management of benign prostatic hyperplasia. J Urol,
173(5):1666 – 1667, 2005.
190.
Kaplan SA: Andropause: endocrinology, erectile dysfunction, and prostate physiology. J
Urol, 173(5):2058 – 2059, 2005.
191.
Kaplan SA: Are indications for prostatectomy in octogenarians the same as for younger men?
J Urol, 173(5):2059, 2005.
192.
Kaplan SA: Chronic inflammation in benign prostate hyperplasia is associated with focal
upregulation of cyclooxygenase – 2, Bcl – 2 and cell proliferation in the glandular epithelium. J
Urol, 173(4): 1266 – 1267, 2005.
193.
Kaplan SA: The effect of combined androgen ablation on the expression of alpha 1A –
adrenergic receptor in the human prostate. J Urol, 173(4): 1267, 2005.
25
194.
Kaplan SA: Three – year follow – up of feedback microwave thermotherapy versus TURP
for clinical BPH: a prospective randomized multicenter study. J Urol, 173(5): 1667 – 1668,
2005.
195.
Kaplan SA, Walmsley K, Te AE: Tolterodine extended release attenuates lower urinary tract
symptoms in men with benign prostatic hyperplasia. J Urol, 174: 2273 – 2276, 2005.
196.
Kaplan SA: In vitro assessment of the efficacy of thermal therapy in human benign prostatic
hyperplasia. J Urol, 174(4): 1352, 2005.
197.
Kaplan SA: High – energy transurethral microwave thermotherapy in patients with benign
prostatic hyperplasia: comparative study between 30 and 60 minute single treatments. J Urol,
174(4): 1352, 2005.
198.
Kaplan SA: Transurethral microwave thermotherapy vs. transurethral resectionfor treating
benign prostatic hyperplasia: a systematic review. J Urol, 174(1):221 – 222, 2005.
199.
Kaplan SA: Intermittent catheterization time required after interstitial laser coagulation of the
prostate. J Urol, 174(1): 222, 2005.
200.
Kaplan SA: The changing practice of transurethral prostatectomy: a comparison of cases
performed in 1990 and 2000. J Urol, 174(1):221, 2005.
201.
Kaplan SA: Development and validation of a quality – of – life scale for Chinese patients with
benign prostatic hyperplasia. J Urol, 174 (1): 224, 2005.
202.
Kaplan SA: Single – blind, randomized controlled study of the clinical and urodynamic effects
of an α – blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic
hyperplasia. J Urol, 174(3): 1011, 2005.
203.
Kaplan SA: Correlation between lower urinary tract symptoms and urethral function in benign
prostatic hyperplasia. J Urol, 174(3): 1010 – 1011, 2005.
204.
Kaplan SA: Induction and function of CYR61 (CCNI) in prostatic stromal and epithelial cells:
CYR61 is required for prostatic cell proliferation. J Urol, 174(3):1012.
205.
Kaplan SA: BPH: Patient perceptions and financial reality regarding the aging American
prostate. J Urol, 173(5):1852, 2005.
206.
Kaplan SA: Efficacy of extended – release doxazosin and doxazosin standard in patients with
concomitant benign prostatic hyperplasia and sexual dysfunction. J Urol, 174 (4): 1353, 2005.
207.
Kaplan SA: Lower urinary tract symptoms: a hermeneutic phenomenological study into men’s
lived experience. J Urol, 174(4): 1353 – 1354, 2005.
208.
Kaplan SA: Prospective randomized controlled trial comparing plasmakinetic vaporesection
and conventional transurethral resection of the prostate. J Urol, 174:679, 2005.
26
209.
Kaplan SA: The 12 – year outcome analysis of an endourethral Wallstent for treating benign
210.
Kaplan SA: Three – dimensional ultrasonography in evaluation of benign prostatic
hyperplasia. J Urol, 174:1904, 2005.
211.
Kaplan SA: Effect of dutasteride on the detection of prostate cancer in men with benign
prostatic hyperplasia. J Urol, 174: 1905, 2005.
212.
Kaplan SA: Patients with a large prostate show a higher prevalence of androgenic alopecia. J
Urol, 174 (5): 1905, 2005.
213.
Kaplan SA: Chronic inflammation in benign prostate hyperplasia is associated with focal
upregulation of cyclooxygenase – 2, Bcl – 2, and cell proliferation in the glandular epithelium.
J Urol, 174:2281, 2005.
214.
Kaplan SA: Comparison of the pharmacological effects of a novel selective androgen receptor
modulator, the 5α – reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in
intact rats: new approach for benign prostate hyperplasia. J Urol, 174:2282, 2005.
215.
Kaplan SA: A comparison of four different α1 – blockers in benign prostate hyperplasia
patients with and without diabetes. J Urol, 174:2282 – 2283, 2005.
216.
Kaplan SA, Walmsley K and Te AE: Tolterodine extended release attenuates lower urinary
tract symptoms in men with benign prostatic hyperplasia. J Urol, 174 (6): 2273 – 2276, 2005.
217.
Capodice JL, Bemis DL, Buttyan R, Kaplan SA, Katz AE: A literature review of
complementary and alternative medicine for chronic prostatitis / chronic pelvic pain syndrome.
Evidence based complementary and alternative medicine. http://ecam.oxfordjournals.org.
October, 2005.
218.
Kaplan SA, DeRose AF, Kirby RS, O’Leary MP, McVary KT: Beneficial effects of extendedrelease doxazosin and doxazosin standard on sexual health. BJU International. BJU Int. 97
(3):559-66, 2006.
219.
Giulliano F, Kaplan SA, Cabanis MJ: Hemodynamic interaction study between the alpha1blocker alfuzosin and the phosphodiesterase 5 inhibitor tadalafil in middle-aged healthy male
subjects. Urology, 67:1199 – 1204, 2006.
220.
Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z: Tolterodine
extended release improves overactive bladder symptoms in continent men with overactive
bladder and nocturia. Urology, 68:328 – 332, 2006.
221.
Kaplan SA: Analysis of the inflammatory network in benign prostate hyperplasia and prostate
cancer. J Urol, 175(3): 1032 – 1033, 2006.
222.
Kaplan SA: Expression of cyclooxygenase – 1 and cyclooxygenase – 2 in the human prostate.
J Urol, 175 (3): 1033, 2006.
27
223.
Kaplan SA: Prospective randomized controlled trial comparing plasmakinetic vaporesection
and conventional resection of the prostate. J Urol 175 (3): 1033 – 1034, 2006.
224.
Kaplan SA: Feedback microwave thermotherapy with the ProstaLund compact device for
obstructive benign prostatic hyperplasia: 12 month response rates and complications. J Urol,
175 (3): 1034 – 1035, 2006.
225.
Kaplan SA: Intraoperative floppy iris syndrome associated with tamsulosin. J Urol, 175: 2213,
2006
226.
Kaplan SA: Prostate size influences the outcome after presenting with acute urinary retention.
J Urol, 175(1): 227 - 228, 2006.
227.
Kaplan SA: Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for
symptomatic benign prostatic hyperplasia (BPH): A European multi – center evaluation. J Urol
175 (3): 1035, 2006.
228.
Kaplan SA: Acute urinary retention: what is the impact on patients’ quality of life? J Urol,
175 (1): 229, 2006.
229.
Kaplan SA: Assessing prostate volume by magnetic resonance imaging. J Urol, in press. 175
(1): 228 – 229, 2006.
230.
Kaplan SA: Urgency of micturition and detrusor contractility in men with prostatic obstruction
and overactive bladders. J Urol, 175(2): 633, 2006.
231.
Kaplan SA: Combination therapy with rofecoxib and finasteride in the treatment of men with
lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). J Urol, 175 (2):
633 – 634, 2006.
232.
Kaplan SA: Activation of Caspases – 3, - 6, and - 9 during finasteride treatment of benign
233.
Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW,
Nyberg LM, for the MTOPS Research group. Relationship between prostate size and the effect
of combination therapy with doxazosin and finasteride versus either drug alone on the clinical
progression of benign prostatic hyperplasia. J Urol, 175:217-221, 2006.
234.
Abrams P, Kaplan SA, De Konig Gans HJ, Millard R: Safety and tolerability of tolterodine for
the treatment of overactive bladder in men with bladder outlet obstruction. J Urol, 175: 999 –
1004, 2006
235.
Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z: Efficacy and
tolerability of tolterodine extended release in male patients with overactive bladder and urgency
urinary incontinence. BJU International, 97:1003 – 1006, 2006.
28
236.
Kaplan SA and Crawford ED: Choosing a safe strategy for androgen supplementation in men
with low testosterone levels associated with the metabolic syndrome and/or type 2 diabetes.
Diabetes Care, 29(3):749, 2006.
237.
Roehrborn CG and Kaplan SA: Optimising the management of patients with benign prostatic
hyperplasia. BJU International 97(2): 1 – 45, 2006.
238.
Kaplan SA, Meehan AG, Shah A: The age-related decline in testosterone is significantly
exacerbated in obese men with the metabolic syndrome? What are the implications of this for
the relatively high incidence of erectile dysfunction observed in these men?" J Urol, 176: 1524
– 1527, 2006.
239.
Kaplan SA: Estradiol / androgen receptors during aging: microsomal distribution in human
benign prostatic hypertrophy. J Urol, 175 (4): 1436, 2006.
240.
Kaplan SA: Dilutional hyponatremia of TURP syndrome: a historical event in the 21st century.
J Urol, 175(5): 1805, 2006.
241.
Kaplan SA: Prostate operations: long term effects on sexual and urinary function and quality
of life. Comparison with an age – matched control population. J Urol, 175(5): 1805, 2006.
242.
Kaplan SA: Transurethral electrovaporization of the prostate: is it any better than standard
transurethral prostatectomy? 5 – year follow – up. J Urol, 175 (5): 1804, 2006.
243.
Kaplan SA: Minimally invasive therapy for benign prostatic hyperplasia: practice patterns in
Minnesota. J Urol, 175 (4): 1437 – 1438, 2006.
244.
Kaplan SA: Treatment of lower urinary tract symptoms suggestive of benign prostatic
hyperplasia: the cardiovascular system. J Urol, 175 (6): 2211, 2006.
245.
Kaplan SA: Androgen regulation of JM – 27 is associated with the diseased prostate. J Urol,
175 (4): 1437, 2006.
246.
Gonzalez RR and Kaplan SA: Tadalafil for the treatment of lower urinary tract symptoms
(LUTS) in men with benign prostatic hyperplasia (BPH). Expert Opin Drug Metab and Toxic.
2(4): 609 – 617, 2006.
247.
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Zhoughong:
Tolterodine and tamsulosin for treatment of lower urinary tract symptoms and overactive
bladder. A randomized controlled trial. JAMA, 296 (19): 2319 – 2328, 2006.
248.
Capodice JL, Jin Z, Bemis DL, Samadi D, Stone BA, Kaplan SA, Katz AE: A pilot study on
acupuncture for lower urinary tract symptoms related to chronic prostatitis / chronic pelvic
pain. Chinese Medicine. 2:1-6, 2007.
249.
Kaplan SA: Curvilinear transurethral ultrasound applicator for selective prostate thermal
therapy. J Urol, 175 (6): 2213 – 2214, 2006.
29
250.
Kaplan SA: Comparison of tamsulosin and naftopidil and safety in treatment of benign
prostatic hyperplasia: a randomized controlled trial. J Urol, 175 (6): 2212 – 2213, 2006.
251.
Kaplan SA: Long - term sustained improvement in symptoms of benign prostatic hyperplasia
with the dual 5α – reductase inhibitor dutasteride: results of 4 – year studies. J Urol, 175 (6):
2211 – 2212, 2006.
252.
Dimitrakov JD, Kaplan SA, Kroenke K, Jackson JL, Freeman MR: Management of chronic
prostatitis/ chronic pelvic pain syndrome: an evidence-based approach. Urology, 67: 881 – 888,
2006.
253.
Gonzalez RR, Kaplan SA: First-line treatment for symptomatic benign prostatic hyperplasia: is
there a particular patient profile for a particular treatment? World J Urol, 24(4):360 – 367,
2006.
254.
Kaplan SA and Neutel J: Vasodilatory factors in the treatment of older men with symptomatic
benign prostatic hyperplasia. Urol, 67:225 – 231, 2006.
255.
Kaplan SA: The economic impact of using alfuzosin 10 mg once daily in the management of
acute urinary retention in the UK: a 6 – month analysis. J Urol, 176 (1): 273, 2006.
256.
Kaplan SA: Lifetime implications and cost – effectiveness of using finasteride to prevent
prostate cancer. J Urol, 176 (1): 274, 2006.
257.
Kaplan SA: Relationship between benign prostatic hyperplasia and lower urinary tract
symptoms and correlation between prostate volume and serum prostate – specific antigen in
clinical routine. J Urol, 176 (3): 1061, 2006.
258.
Kaplan SA: Erectile dysfunction (ED) is prevalent, bothersome and under diagnosed in
patients consulting urologists for benign prostatic syndrome (BPS). J Urol, 176 (1): 274 – 275,
2006.
259.
Kaplan SA: Resistance index in benign prostatic hyperplasia using power Doppler imaging
and clinical outcomes after transurethral vaporization of the prostate. J Urol, 176 (2): 675,
2006.
260.
Kaplan SA: Measuring resistance index in patients with BPH and lower urinary tract
symptoms. J Urol, 176 (2): 676, 2006.
261.
Kaplan SA: Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and
acute urinary retention: a population – based cohort study in the Netherlands. J Urol,
176(3):1061, 2006.
262.
Kaplan SA: Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign
prostatic hyperplasia. J Urol, 176 (2): 676 – 677, 2006.
263.
Kaplan SA: Alfuzosin 10 mg once daily in the management of acute urinary retention: results
of a double – blind placebo – controlled study. J Urol, 176 (2): 1062 – 1063, 2006.
30
264.
Kaplan SA: The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and
decreases relative cancer volume in human prostate. J Urol, 176 (2): 677, 2006.
265.
Kaplan SA: Long – term follow – up study to evaluate the efficacy and safety of the
doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with
or without concomitant hypertension. J Urol, 176 (2): 678, 2006.
266.
Kaplan SA and Naslund M: Public, patient, and professional attitudes towards the diagnosis
and treatment of enlarged prostate: a landmark study. J Clin Pract 60 (10):1157 – 1165, 2006.
267.
Kaplan SA: Voiding symptom evaluation: it is time to recalibrate. Eur Urol, June, 2006.
268.
Kaplan SA: Comparison of standard transurethral resection, transurethral vapour resection and
holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of > 40 g.
J Urol, 176(4:1):1511, 2006.
269.
Kaplan SA: Long – term therapy with the dual 5α - reductase inhibitor dutasteride is well
tolerated in men with symptomatic benign prostatic hyperplasia. J Urol, 176 (5): 2123, 2006.
270.
Kaplan SA: A shifted paradigm for the further understanding, evaluation and treatment of
lower urinary tract symptoms in men: focus on the bladder. J Urol, 176 (6): 2571, 2006.
271.
Kaplan SA: Retinoic acid via RARα inhibits the expression of 24-hydroxylase in human
prostate stromal cells. J Urol, 176 (6): 2572, 2006.
272.
Kaplan SA: Immunohistochemical expression of tumor antigens MAGE – AI, MAGE – A3/4
and NY – ESO – I in cancerous and benign prostatic tissue. J Urol, 176 (6): 2573 – 2574, 2006.
273.
Kaplan SA: Photoselective vaporization of the prostate in the treatment of benign prostatic
hyperplasia. J Urol, 176(4:1): 1510, 2006.
274.
Kaplan SA: Vascular damage as a risk factor for benign prostatic hyperplasia and erectile
dysfunction. J Urol, 176 (6): 2572 – 2573, 2006.
275.
Kaplan SA: The impact of medical therapy on surgery for benign prostatic hyperplasia: a study
comparing changes in a decade (1992 – 2002). J Urol, 176 (5): 2123 – 2124, 2006.
276.
Kaplan SA: Long – term efficacy and safety of a combination of sabal and urtica extract for
lower urinary tract symptoms – a placebo – controlled, double – blind, multicenter trial. J Urol,
176 (6): 2571 – 2572, 2006.
277.
Kaplan SA: Simultaneous administration of vardenafil and tamsulosin does not induce
clinically significant hypotension in patients with benign prostatic hyperplasia. J Urol, 176 (5):
2122, 2006.
278.
Kaplan SA: Male pelvic health: A urologic call to arms. J Urol, 176 (6): 2351 – 2352, 2006.
31
279.
Staskin DR, Kaplan SA, Wein AJ: Antimuscarinic therapy in men with bladder outlet
obstruction. Current Urology Reports, 6:437 – 439, 2006.
280.
Kaplan SA: Three months’ treatment with the α1 – blocker alfuzosin does not affect total or
transition zone volume of the prostate. J Urol, 177 (1): 234, 2007.
281.
Kaplan SA: Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient
quality of life and discomfort, in clinical practice. J Urol in press. 177 (1): 235, 2007.
282.
Kaplan SA: Effects of α1 – adrenoreceptor antagonists in male sexual function. J Urol, 177(2):
623 – 624, 2007.
283.
Kaplan SA: Association of anthropometric measures with the presence and progression of
benign prostatic hyperplasia. J Urol, 177 (2): 624 – 625, 2007.
284.
Kaplan SA: Metabolic factors associated with benign prostatic hyperplasia. J Urol, 177 (2):
623 – 624, 2007.
285.
Kaplan SA: Relationship between serum specific antigen and the pattern of inflammation in
both benign and malignant prostatic disease in Middle Eastern men. J Urol, 177 (3): 1055 –
1056, 2007.
286.
Kaplan SA: Intraprostatic injection of botulinum toxin type – A relieves bladder outlet
obstruction in human and induces prostate apoptosis in dogs. J Urol, 177 (1): 235 – 236, 2007.
287.
Kaplan SA: Identification of the patients with enlarged prostate: Diagnosis and treatment
strategies. Osteopathic Medicine and Primary Care 1:11, 2007.
288.
Kaplan SA: New data: do recent findings dispel questions about treating overactive bladder in
men. Eur Urol Supplements 6: 10 – 16, 2007.
289.
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Zhoughong:
Tolterodine and tamsulosin for treatment of lower urinary tract symptoms and overactive
bladder. A randomized controlled trial. Response to Letter. JAMA: 297 (11): 1191 – 1193,
2007.
290.
Kaplan SA, Gonzalez RR, Te AE: Combination of an alpha -1 blocker, alfuzosin and a PDE
– 5 inhibitor, sildenafil citrate is superior to monotyherapy in treating lower urinary tract
symptoms and sexual dysfunction. Eur Urol, 51: 1717 –1723, 2007.
291.
Kaplan SA: Metabolic dysfunction and male pelvic health. Eur Urol, 52:316 –317, 2007.
292.
Rosenberg, MT, Staskin DR, Kaplan SA, MacDiarmid SA, Newman DK, Ohl DA: A practical
guide to the evaluation of male lower urinary tract symptoms in the primary care setting. IJCP,
61 (9): 1535 – 1546, 2007.
293.
Kaplan SA: PDE – 5 inhibitors will have a beneficial effect in men with BPH. Eur
32
294.
Kaplan SA: Botulinum toxin for the treatment of lower urinary tract symptoms due to benign
prostatic hyperplasia. J Urol, 179 (1): 236, 2008.
295.
Kaplan SA: The effects of dutasteride, tamsulosin, and combination therapy on lower urinary
tract symptoms in men with BPH and prostatic enlargement: two – year results from the
Combination of Avodart (dutasteride and tamsulosin (CombAT) study. J Urol, 179:620 – 621,
2008.
296.
Kaplan SA, Wein AJ, Staskin DR, Roehrborn CG, Steers WD: Urinary retention and post void
residual in men: separating truth from tradition. J Urol, in press.
297.
Roehrborn CG, Kaplan SA, Kraus SR, Wang JT, Bavendam T, Guan Z: The effects of serum
prostate-specific antigen level on the efficacy of tolterodine extended release with or without
tamsulosin in men with lower urinary tract symptoms including overactive bladder. Urology, in
press.
298.
Cinar A, Hall SA, Link CL, Kaplan SA, Kopp ZS, Roehrborn CG, Rosen RC: Cluster analysis
and lower urinary tract symptoms (LUTS) in men: findings from The Boston Area Community
Health (BACH) Survey. BJU Int, in press
299.
Hall SA, Cinar A, Link CL, Kopp ZS, Roehrborn CG, Kaplan SA, Rosen RR: Do urologic
symptoms cluster among women? Results from the Boston Area Community Health (BACH)
Survey. BJU Int, in press.
300.
Roehrborn CG, Kaplan SA, Jones JS, Wang JT, Bavendam T, Guan Z: Tolterodine extended
release with or without tamsulosin in men with lower urinary tract symptoms including
overactive bladder: effects of prostate size. Eur Urol, in press.
301.
Chapple CR, Wein AJ, Abrams PH, Dmochowski RR, Giuliano F, Kaplan SA, McVary KT,
Roehrborn CG: Lower urinary tract symptoms revisised: a broader clinical perspective.
Neurourolo Urodynam, in press.
302.
Kaplan SA, Roehrborn CG, McConnell JD, Meehan AG, Surynawashi S, Lee JY, Rotonda J,
Kusek JW, Nyberg LM, for the Medical Therapy of Prostatic Symptoms (MTOPS) Research
Group: Long-term treatment with finasteride results in a clinically significant reduction in total
prostate volume compared to placebo over the full range of baseline prostate sizes in men
enrolled in the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. J Urol, in press.
303.
Rovner E, Kreder K, Sussman D, Kaplan SA, Carlsson M, Bavendam T, Guan Z: Effect of
tolterodine extended release with or without tamsulosin on measures of urgency and patient –
reported outcomes in men with lower urinary tract symptoms. J Urol, submitted.
304.
Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z: Tolterodine
extended release with or without tamsulosin in men with lower urinary tract symptoms and
overactive bladder: effects on urinary symptoms assessed by the International Prostate
Symptom Score. BJU Int, in press.
33
305.
Zoltan E and Kaplan SA: Ovreactive bladder and the effects of prostate volume. Current
Bladder Dysfuction Reports, in press.
306.
Saini R and Kaplan SA: Lower urinary tract symptoms in men and incontinence in men. Up to
date for Primary Care, in press.
307.
Kaplan SA: Holmium laser enucleation versus transurethral resection of the prostate: results
from a 2 – center, prospective, randomized trisl in patients with obstructive benign prostatic
hyperplasia. Editorial. J Urol, in press.
Invited Articles
1.
Kaplan SA, Blaivas JG: Bladder dysfunction in patients with multiple sclerosis. Contemporary
Urology. 2:14 - 19, 1989.
2.
Kaplan SA, Brown WC, Blaivas JG: Management of bladder dysfunction in stroke patients.
Contemporary Urology. 47 - 50, 1990.
3.
Kaplan SA, Blaivas JG: Management of BPH. Hospital Medicine. May 77 - 86, 1990.
4.
Chancellor MB, Kaplan SA, Blaivas JG: Detrusor-external sphincter dyssynergia. CIBA
Symposium, Neurobiology of Incontinence, June, 1990.
5.
Kaplan SA, Koo HP: Prostatic Stents. In: Surgical Techniques in Urology. Volume 3: Issue 4
October 1990.
6.
Kaplan SA and Lepor H: Prostate treatment without surgery. Executive Good Health Report,
1990.
7.
Stein BS, Stone NN and Kaplan SA: Update on Prostatic Disease: Benign Prostatic hyperplasia.
Miles Publications. 1991.
8.
Kaplan SA, Ring KS, Sawczuk, IS: The use of a titanium prostatic stent in the management of
acute urinary retention. Video Urology June 1991.
9.
Kaplan SA, Te A: Bladder dysfunction in diabetes. Problems in Urology. September 1992.
10.
Kaplan SA, Ring KS, Sawczuk IS: Titanium Stent in urinary retention. Video Urology Times.
5:1, 1992.
11.
Kaplan SA: Transrectal hyperthermia in the management of benign prostatic hyperplasia.
Urologue, September 1992.
12.
Kaplan SA: Transrectal hyperthermia: Current Concepts. Contemporary Urology. March 1993.
13.
Kaplan SA: Prostatic urethral stents. Contemporary Urology. April 1993.
34
14.
Kaplan SA: Evaluation: the role of symptoms and urodynamic evaluation of benign prostatic
hypertrophy. AUA/Merck Consultant Urologist, 1993.
15.
Kaplan SA, Shabsigh R, Soldo KA and Olsson CA: Prostatic and Periprostatic Interstitial
Temperature Measurements Treated with Transrectal Thermal Therapy (Local Intracavitary
Microwave Hyperthermia). Urology/Nephrology Digest, March, 1993
16.
Kaplan SA: Prostatic urethral stents. Semi Urol 12 (3):193-9, 1994.
17.
Te AE and Kaplan SA: Transurethral electrovaporization of the prostate (TVP): A novel
modification of the standard TURP. Cont Urol 1995 May 7:74-83.
18.
Te AE and Kaplan SA: Electrovaporization of the prostate. Video Urology. October, 1995
19.
Kaplan SA: BPH: Options for Care. AUA Today. September, 1995.
20.
Te AE and Kaplan SA: Transurethral electrovaporization of the prostate: State of the art
electrosurgery. Current Opinion in Urology. January, 1997.
21.
Santarosa RP, Te AE and Kaplan SA: Minimally invasive procedures for benign prostatic
hyperplasia: electrovaporization, lasers, heat therapy and stents. In: Mediguide for Urology. Ed:
Carson CC. 1996; 9:1-6.
22.
Santarosa RP and Kaplan SA: Modified vaginal - wall sling for repair of vaginal prolapse.
Current Surgical Techniques in Urology. July, 1996.
23.
Santarosa RP and Kaplan SA: Urology Board review - BPH. Hospital Physician, November,
1996.
24.
Kaplan SA: BPH: Where are we in 1996? AUA Today. 1:3 1996.
25.
Hendricks JG and Kaplan SA: Erectile dysfunction and incontinence after radical retropubic
prostatectomy. Contemporary Urology, 9:13 - 22, 1997.
26.
Kaplan SA: Urodynamic and clinical effects of terazosin therapy in symptomatic patients with
and without bladder outlet obstruction. Editorial. Urology. 49:431, 1997.
27.
Kaplan SA: The postoperative morbidity of transurethral resection of the prostate and of four
“minimally invasive” treatment alternatives. Editorial Comment. J Urol, 158:105, 1997.
28.
Kaplan SA: Voiding symptoms: Why do men under the age of 50 have them? Issues in
Incontinence 4:1, 1997.
29.
Te AE and Kaplan SA: Electrovaporization of the Prostate. Endourology on CD - ROM. 1:1,
1997.
30.
Kaplan SA and Goluboff EG: Urology Board Review - Neurogenic Bladder (part 1). Hospital
Physician, May (volume 5), 1997.
35
31.
Te AE and Kaplan SA: Electrovaporization of the prostate. Mayo Clinic Proceedings. 73:691 –
695, 1998.
32.
Kaplan SA: Pharmacologic Management of BPH. AUA Today. October, 1997.
33.
Kaplan SA and Klein LT: Practical Cases in Urology - Practical Management of BPH.
November, 1997.
34.
Kaplan SA: Management of high – risk patients with benign prostatic hyperplasia: Long – term
experiences with the Memotherm stent. Editorial comment. J Urol, 1998.
35.
Cooper KL, McKiernan JM, Kaplan SA: Alpha adrenoreceptor antagonists in the treatment of
benign prostatic hyperplasia. DRUGS, January 57 (1): 9- 17, 1999.
36.
Kaplan SA: Transurethral resection of the prostate vs. transurethral electrovaporization of the
prostate: A blinded, prospective comparative study with 1 – year follows – up. Response to letter.
J. Urol, November, 1998.
37.
Kohn IJ and Kaplan SA: The potential clinical utility of iontophoretic drug delivery for urologic
procedures. Contemporary Urology, November, 1998.
38.
Kaplan SA: The impact of the new paradigm in pharmacological management. New Concepts in
the medical management of BPH. Johns Hopkins Press, 1998.
39.
Kohn IJ and Kaplan SA: Female sexual dysfunction: what is known and what remains to be
determined. Contemporary Urology. October, 1999.
40.
Kaplan SA: Benign prostatic hyperplasia: transurethral treatment. Objectives for Urology
Residency Education. Ed: Wein, AJ. 1999.
41.
Choi J, Ikeguchi EF, Te AE, Kaplan SA: Review of laser prostatectomy. Urology Review, July,
1999.
42.
Kohn IJ and Kaplan SA: Female sexual dysfunction: what is known and what remains to be
determined. Contemporary OB/GYN. Vol 45:2, 2000.
43.
Cabelin MA, Te AE, Kaplan SA: Benign prostatic hyperplasia: Challenges for the new
millennium. Current Opinion in Urology. 10:301-306, 2000.
44.
Cabelin MA, Te AE, Kaplan SA: Transurethral electrovaporization of the prostate. Current
Opinion in Urology. 10:306 – 310, 2000.
45.
Kaplan SA: What makes us different? Curr Urol Rep 1(1): 1 – 2, 2000.
46.
Kaplan SA: Benign prostatic hyperplasia: many new options, same old approach. Curr Urol Rep
1(2):83, 2000.
36
47.
Cabelin MA, Te AE, Kaplan SA: Transurethral electrovaporization of the prostate. Current
Urology Reports. 1(2): 116 – 23, 2000.
48.
Volpe MA, Fromer D, Kaplan SA: Holmium and interstitial lasers for the treatment of BPH: a
laser revival. Current Opinion in Urology. 11(1): 43 – 8, 2001.
49.
Cabelin M and Kaplan SA: Benign prostate hyperplasia: Update on new technology.
Contemporary Urology. May, 2001.
50.
Kaplan SA: Human comfort: more than modern technology. Curr Urol Rep 2(6): 413 – 414,
2001.
51.
Blute ML, Jacobsen SJ, Kaplan SA, Lowe FC, O’Leary MP, Steers WD, Roehrborn, CG:
Introduction to new therapies for BPH. Urology, 58(6) 1 – 4, 2001.
52.
Fromer D and Kaplan SA: Benign prostatic hyperplasia. In: Conn’s textbook of Medicine. 2002.
53.
Kaplan SA: Female Sexual dysfunction. Patient Care, February, 2002.
54.
Lam J, Volpe, Kaplan SA: Stents in the management of men with BPH. Current Urology Reports,
2 (4): 277 – 84, 2001.
55.
Littlejohn JO, Ghafar MA, Kang YM, Kaplan SA: TURP: The new old standard. Current
Opinion in Urology. 2002, 12:19 – 23.
56.
Lam JS, Volpe MA, Kaplan SA: Transurethral resection and incision of the prostate. Atlas of the
Urologic Clinics of North America 10: 27 – 43, 2002.
57.
Cabelin MA, Ghafar MA, Te AE, Kaplan SA : Transurethral vaporization of the prostate. Atlas of
the Urologic Clinics of North America 10: 45 – 49, 2002.
58.
Kaplan SA: Alpha blocker therapy for BPH. AUA News, November 2002.
59.
Kaplan SA: Reproducibility and clinical and concurrent validity of the MSF- 4: a four- item male
sexual function questionnaire for patients with benign prostatic hyperplasia. J Urol. 2002
Oct;168(4 Pt 1):1661-2.
60.
Kaplan SA: Minimally invasive therapies for benign prostatic hyperplasia in the new
millennium: long term data J Urol. 2002 Oct;168(4 Pt 1):1661.
61.
Kaplan SA: Practice trends in the management of prostate disease by family practice
physicians and general internists: an Internet-based study.J Urol. 2002 Oct;168(4 Pt 1):1660-1.
62.
Kaplan SA: Effects of finasteride and cyproterone acetate on hematuria associated with benign
prostatic hyperplasia: a prospective, randomized, controlled study. J Urol. 2002 Oct;168(4 Pt
1):1660.
37
63.
Kaplan SA: Quality of life of patients on the waiting list for benign prostatic hyperplasia
surgery. J Urol. 2002 Oct;168(4 Pt 1):1659-60.
64.
Kaplan SA: Localization of angiotensin-converting enzyme in the human prostate: pathological
expression in benign prostatic hyperplasia. J Urol. Oct;168:1659, 2002.
65.
Kaplan SA: Characterization of cultured human prostatic epithelial cells bycluster designation
antigen expression. J Urol. 2002 Oct;168(4 Pt 1):1658-9.
66.
Kaplan SA: Effects of mepartricin on estradiol and testosterone serumlevels and on prostatic
estrogen, androgen and adrenergic receptor concentration in adult rats. J Urol. 168(4 Pt
1):1658, 2002.
67.
Kaplan SA: Terazosin for treating symptomatic benign prostatic obstruction: a systematic
review of efficacy and adverse effects. J Urol. 2002 Oct: 168(4 Pt 1):1657-8.
68.
Kaplan SA: Comparison of long-term results of transurethral incision of theprostate with
transurethral resection of the prostate, in patients with benign prostatic hypertrophy. J Urol.
2002 Oct;168(4 Pt 1):1657.
69.
Littlejohn JO and Kaplan SA: An unexpected association between urinary incontinence,
depression, and sexual dysfunction. Drugs Today, February, 2003.
70.
Ogiste JS, Cooper KL, Kaplan SA: Are stents still a useful therapy for BPH? Current Opinion in
Urology, 13 (1): 51 – 57, 2003.
71.
Kaplan SA: BPH medical therapy in 2003. AUA News, April, 2003.
72.
Kohn IJ, Te AE, Kaplan SA : Electrical stimulation and neuromodulation in the treatment of
lower urinary tract dysfunction. AUA Updates, Volume XXII, #9, 2003.
73.
Kaplan SA: Men’s health: new insights into BPH and sexual function. Medical Education
Resources, September, 2003.
74.
Kaplan SA: Molecular marker for interstitial cystitis. AUA News, September, 2003.
75.
Cooper KL, Anastasiadis AG and Kaplan SA: Minimally invasive therapies for BPH:
variations of the same theme? Contemporary Urology, April, 2004.
76.
Lam JS, Cooper KL, Kaplan SA: Changing aspects in the evaluation and treatment of patients
with benign prostatic hyperplasia. Medical Clinics of North America, 88(2):281 – 309, 2004.
77.
Kaplan SA: BPH : new paradigms, new approaches. Urology Times 31(11), 2003.
78.
Kaplan SA: Medical management of BPH: New paradigms, new approaches. Urology Times,
November, 2003.
79.
Kaplan SA: Prostate histopathology. J Urol, 171:1385, 2004.
38
80.
Gjertsen CK, Walmsley K, Kaplan SA: BPH: An update on diagnosis and therapeutic options.
Cleveland Clinic Review, 71(11), 2004.
81.
Walmsley K, Gjersten CK, Kaplan SA: Medical management of BPH – an update. AUA Update,
November, 2004.
82.
Kaplan SA: BPH management in 2004. AUA News, November 2004.
83.
Kaplan SA: Concomitant use of an artificial urinary sphincter device and a Urolume for men
with sphincteric incontinence. AUA News, December, 2004.
84.
Kaplan SA: An update of the AUA Guidelines. Medical Reviews, 7(6): 324-354, 2004.
85.
Kaplan SA: The relationship between sexual function and voiding function: implications for
diagnosis and treatment. AUA News, March, 2005.
86.
Jaffe W and Kaplan SA: The Epidemiology and Pathophysiology of Benign Prostatic
Hyperplasia. Atlas of the Prostate, 3rd edition. July, 2005.
87.
Kaplan SA: Factors predicting failure with medical therapy for BPH. Medical Reviews. 7(7): 534
– 539, 2005.
88.
Kaplan SA: Alpha blocker therapy: Current Update. Medical Reviews, 7(8):534 – 542, 2005.
89.
Rusnack SL, Kaplan SA: The use of botulinum toxin in men with benign prostatic hyperplasia.
Medical Reviews, November, 2005.
90.
Kaplan SA: Association between LUTS and sexual function. Scientific World Journal.
December, 2005.
91.
Kaplan SA: The role of muscarinic receptor antagonists in the treatment of men with lower
urinary tract symptoms secondary to BPH. American Journal of Urology, 3:11:8, November
2005.
92.
Kaplan SA and Roehrborn CG: Optimizing the management pf patients with benign prostatic
hyperplasia. BJU supplement, April, 2006i.
93.
Kaplan SA: Benign prostatic hyperplasia guidelines: how can they be useful to primary care.
Cornell Urology Reports on Men’s Health, Volume 1:1, 2006.
94.
Kaplan SA: Medical therapy for benign prostatic hyperplasia: new terminology, new
concepts, better choices. Medical Reviews, 8 (1):2006.
95.
Kaplan SA and Gonzalez RR: PDE – 5 Inhibitors for the Treatment of Lower Urinary Tract
Symptoms (LUTS) in Men with Benign Prostatic Hyperplasia (BPH). AUA News 11(3): 25 –
27, 2006.
39
96.
Kaplan SA: Editorial comment RE: Hartung R, et al: Age, comorbidity and hypertensive comedication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. J Urol, 175:
624 – 628, 2006.
97.
Jaffe WI and Kaplan SA: Benign prostatic hyperplasia: markers of progression. AUA Update,
in press.
98.
Kaplan SA: Evolving insights into male LUTS. AUA News, November 2006
99.
Kaplan SA: BPH 2006: are we treating a new disease? AUA News, October, 2006
100.
Kaplan SA and Gonzalez RR: PDE5 inhibitors for the treatment of male lower urinary tract
symptoms. Reviews in Urology, 8 (suppl 3): S3 – S8, 2006.
101.
Kaplan SA: Different indications and settings for photoselective vaporization prostatectomy
(PVP). Med Reviews, 8(3): S3 – S7, 2006.
102.
Kaplan SA: An update on the American Urological Association guidelines for the treatment of
BPH. Med Reviews, in press.
103.
Kaplan SA: Men’s theories about benign prostatic hyperplasia and prostate cancer following a
benign prostatic hyperplasia decision aid. J Urol, 177 (3): 1056 – 1057. 2007.
104.
Kaplan SA: Saw palmetto – induced pancreatitis. J Urol, 177 (2): 625 – 626, 2007.
105.
Kaplan SA: Immunohistochemical detection of cysteine – rich secretory protein 3 in tissue and
in serum from men with cancer or benign enlargement of the prostate gland. J Urol, 177 (3):
1055, 2007.
106.
Kaplan SA: Pre – clinical evidence for the use of phosphodiesterase – 5 nhibitors for treating
benign prostatic hyperplasia. J Urol, 177 (4): 1430 – 1431, 2007.
107.
Kaplan SA: Hyperinsulinemia and dyslipidemia in non – diabetic benign prostatic hyperplasia.
J Urol, 177 (4): 1431 – 1432, 2007.
108.
Kaplan SA: Turbulent urinary flow in the urethra could be a causal factor for benign prostatic
hyperplasia. J Urol, 177 (4): 1432 – 1433, 2007.
109.
Kaplan SA: Impact of surgical treatment on nocturia in men with benign prostatic obstruction.
J Urol, 177 (5): 1823, 2007
110.
Kaplan SA: Relation between acute urinary retention, chronic prostatic inflammation and
accompanying elevated prostate – specific antigen. J Urol, 177 (5):1824, 2007.
111.
Kaplan SA: Comparative study of zinc levels in benign and malignant lesions of the prostate. J
Urol, 177 (5): 1824 – 1825, 2007.
112.
Kaplan SA: Survey on the Italian outpatient urologists regarding the management of benign
prostatic hyperplasia. J Urol, 177 (6): 2247 – 2248, 2007.
40
113.
Kaplan SA: The thermo – expandable metallic stent for managing benign prostatic
hyperplasia: a systematic review. J Urol, 177 (6): 2248, 2007.
114.
Kaplan SA: Analysis of prognostic factors regarding the outcome after a transurethral
resection for symptomatic benign prostatic enlargement. J Urol, 177 (6): 2249, 2007.
115.
Kaplan SA: Inhibition of testosterone induced hyperplasia of the prostate of Sprague – Dawley
rats by pumpkin seed oil. J Urol, 177 (4): 1582 – 1583, 2007.
116.
Kaplan SA: Transurethral microwave thermotherapy effectiveness in small prostates. J Urol,
178:222 – 223, 2007.
117.
Kaplan SA: Tolterodine and tamsulosin for treatment of men with lower urinary tract
symptoms and overactive bladder: A randomized controlled trial. J Urol, 178 (2): 587 – 588,
2007.
118.
Kaplan SA: Naftopidil monotherapy vs. naftopidil and an anticholinergic agent
combined therapy for storage symptoms associated with benign prostatic hyperplasia: a
prospective randomized controlled trial. J Urol, 178 (2): 588 – 589, 2007.
119.
Kaplan SA: Simple case definition of clinical benign prostatic hyperplasia, based on
international prostate symptom score, predicts general practitioner consultation rates. J Urol,
178(3): 1005 – 1006, 2007.
120.
Kaplan SA: Randomized trial comparing holmium laser enucleation of prostate with
plasmakinetic enucleation of prostate for treatment of benign prostatic hyperplasia. J Urol, 178:
223 – 224, 2007.
121.
Kaplan SA: Racial differences in pathogenetic mechanisms, prevalence, and progression of
benign prostatic hyperplasia. J Urol, 178 (3): 1007, 2007.
122.
Kaplan SA: Linguistic adaptation and validation of the Spanish version of the benign
hyperplasia – patient impact measure (BPH – PIM). J Urol, 178 (3): 1006, 2007.
123.
Kaplan SA: Are lower urinary tract symptoms associated with erectile dysfunction in aging
males of Taiwan? J Urol, 178 (3): 1007 – 1008, 2007.
124.
Kaplan SA: Long term results of medical treatment in benign prostatic hyperplasia. J Urol,
178(2):586 – 587, 2007.
125.
Lee R, Saini R, Kaplan SA, Te AE: Review of transurethral microwave thermotherapy. AUA
Update, August, 2007.
126.
Kaplan SA: Characteristics of patients presenting with LUTS / BPH in six European countries.
J Urol, 178 (4): 1387 - 1388, 2007.
127.
Kaplan SA: Occupational risk factors for prostate cancer and benign prostatic hyperplasia: a
case – control study in Western Australia. J Urol, 178 (4): 1388 - 1389.
41
128.
Kaplan SA: α1 – adrenergic receptor antagonists and the iris: new mechanistic insights into
floppy iris syndrome. J Urol, 178 (6): 2505 – 2506, 2007.
129.
Kaplan SA: Diet and benign prostatic hyperplasia: implications for prevention. J Urol, 178 (6):
2506, 2007.
130.
Kaplan SA: Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a
prospective cohort study of Air Force veterans. J Urol, 178 (4): 1389 - 1390.
131.
Kaplan SA: PSA velocity in conservatively managed BPH: can it predict the need for BPH –
related invasive therapy? J Urol, 178 (5): 2057 – 2058, 2007.
132.
Kaplan SA: Bipolar transurethral resection of prostate in saline: preliminary report on clinical
efficacy and safety at 1 year. J Urol, 178 (6): 2506 – 2507, 2007.
133. Kaplan SA: Pygeum africanum extract inhibits proliferation of human cultured prostatic
fibroblasts and myofibroblasts. J Urol, 178 (5): 2058 – 2059, 2007.
134. Kaplan SA: Evidence of a novel biomarker, αs1 – Casein, a milk protein, in benign prostate
hyperplasia. J Urol, 178 (5): 2059, 2007.
135. Kaplan SA: Intake of selected micronutrients and the risk of surgically treated benign prostatic
hyperplasia: a case – controlled study from Italy. J Urol, 178 (6): 2507 – 2508, 2007.
136.
Kaplan SA: CYR61, a cellular proliferation marker in dogs with prostate disease. J Urol,
178:351. 2007.
137.
Kaplan SA: Male Lower Urinary Tract Symptoms: New Approaches. Medscape, September,
2007.
138.
Kaplan SA: Male pelvic health: Review of AUA course. AUA News, December, 2007.
139.
Kaplan SA: The placebo effect in the pharmacologic treatment of patients with lower urinary
tract symptoms. J Urol, 179 (1): 236 – 237, 2008.
140.
Kaplan SA: Effect of tolterodine in preventing urge incontinence immediately after
prostatectomy. J Urol, 179 (1): 237 – 238, 2008.
141.
Kaplan SA: Efficacy and safety of combined therapy with terazosin and tolterodine for
patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a
prospective study. J Urol, 179 (1): 237 – 238, 2008.
142.
Kaplan SA: Fruit and vegetable consumption, intake of micronutrients, and benign prostatic
hyperplasia in US men. J Urol, 179 (1): 238 – 239, 2008.
143.
Kaplan SA: Bipolar transurethral resection of the prostate – technical modifications and early
clinical experience. J Urol, 179 (2): 624, 2008.
42
144.
Kaplan SA: Is the short - term outcome of transurethral resection of the prostate affected by
preoperative degree of bladder outlet obstruction, status of detrusor contractility or detrusor
overactivity? J Urol, 179 (2): 625, 2008.
145.
Kaplan SA: The correlation between metabolic syndrome and prostatic growth with benign
prostatic hyperplasia. J Urol, in press.
146.
Kaplan SA: Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? J Urol,
in press.
147.
Kaplan SA: Changes of sexual function in patients before and after Ho:YAG l l laser
enucleation of the prostate. J Urol, 179(2): 625 – 626, 2008.
148.
Kaplan SA: Atherosclerosis as a risk factor for benign prostatic hyperplasia. J Urol, in press.
149.
Kaplan SA : Treating patients with overactive bladder syndrome with antimuscarinics: heart
rate considerations. J Urol, in press.
150.
Kaplan SA: Resting heart rate in cardiovascular disease. J Urol, in press.
151.
Kaplan SA: Acute urinary retention: medical management and the identification of risk factors
for prevention. J Urol, in press.
152.
Kaplan SA: A large retrospective analysis of acute urinary retention and prostate – related
surgery in BPH patients treated with 5 – alpha reductase inhibitors: dutasteride versus
finasteride. J Urol, in press.
153.
Kaplan SA: Durability of 30 – minute high energy transurethral microwave therapy for
treatment of benign prostatic hyperplasia: a study of 213 patients with or without urinary
retention. J Urol, in press.
154.
Kaplan SA: Efficacy and tolerability of the dual 5α - reductase inhibitor, dutasteride, in the
treatment of benign prostatic hyperplasia in African – American men. J Urol, in press.
155.
Kaplan SA: Safety and effectiveness of photoselective vaporization of the prostate in patients
on ongoing oral anticoagulation. J Urol, in press.
156.
Kaplan SA: Prevalence of lower urinary tract symptoms and effect on quality of life in a
racially and ethnically diverse random sample. J Urol, in press.
157.
Kaplan SA: Obesity and benign prostatic enlargement: a large observational study in China. J
Urol, in press.
158.
Kaplan SA: Sustained beneficial effects of intraprostatic botulinum toxin type A on lower
urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. J Urol, in
press.
159.
Kaplan SA: Evaluation of short term clinical effects and presumptive mechanism of botulinum
toxin type A as a treatment modality of benign prostatic hyperplasia. J Urol, in press.
43
160.
Kaplan SA: Silodosin, a new α 1A - adrenoreceptor – selective antagonist for treating benign
prostatic hyperplasia: results of a phase III randomized, placebo – controlled, double – blind
study in Japanese men. J Urol, in press.
161.
Kaplan SA: The changing world of medical therapy for symptomatic benign prostate
hyperplasia. Cornell Urology Men’s Health for Primary Care Physicians, in press.
Books, book chapters and reviews
Books
•
•
•
Benign Prostatic Hyperplasia: Laser and Heat Therapy. Eds: Paul Miller, Ian Eardley, Steven
Kaplan. Martin Dunitz LTD, 2001
Minimally Invasive Treatments in Urology Eds: Steven Kaplan, Alan Partin, Anthony Atala, 2005
Atlas of the Urologic Clinics of North America. Eds: Mark A. Cabelin and Steven Kaplan, 2003
Book Chapters
1.
Hensle TW, Kaplan SA: Surgical on the lower ureter: an overview. In: Genitourinary Surgery.
Ed: Droller. 1991.
2.
Hensle TW, Kaplan SA: Lower ureteral reconstruction and reimplantation. In: Genitourinary
Surgery. Ed: Droller. 1991.
3.
Kaplan SA, Benson MC: The urologic manifestations of AIDS. AIDS and Rehabilitative
Medicine. Ed. Mukand JM. McGraw-Hill. 1992.
4.
Kaplan SA: Bladder dysfunction. Lebovitz H. Ed., Therapy for Diabetes Mellitus and Related
Disorders. American Diabetes Association. page: 288, 1992.
5.
Kaplan SA: Prostatic Endoprostheses: In: Alternative Treatment of BPH. Ed: Vaughan ED and
Romas N: May, 1993.
6.
Kaplan SA: The neurogenic bladder. Current Therapy in Urology. Ed.: Steer WD. Gower Press.
1993
7.
Kaplan SA: Non-medical alternative therapy in BPH. In: Nephrology and Urology in the Aged
Patient. Oreopolous DG, Michelis, MF and Herschorn, S (eds.). Ch. 58, pp:523-44, 1993.
8.
Kaplan SA, Blaivas JG, Bruer A: Urogenital physiology. In: Rehabilitation Medicine. Ed:
Downey. January, 1994.
9.
Kaplan SA, Dowd, JB: Non medical, alternative therapy for BPH. In: Handbook for BPH, Ed:
Chisolm, G. Raven-Gower press, New York. May, 1994.
10.
Kaplan SA, Blaivas JG: The evaluation and management of the neurogenic bladder. Pang D (ed.)
Disorders of the Pediatric Spine. Raven Press, 1994.
44
11.
Kennedy WC, Kaplan SA, Benson MC: Renal and Urologic Aspects of HIV Infection. In: HIV
and the Kidney. Eds: Kimmel PL and Berns. Churchill Livingstone, 1994.
12.
Te AE and Kaplan SA: Pharmaceutical treatment of BPH and its effect on indications for
prostate surgery. Surgical Technology International, 3rd Edition. Szabo Z, Kerstein MD, Lewis
JE, Eds. Universal Medical Press, Inc. San Francisco, 1994.
13.
Kaplan SA and Bowers DL: Themotherapy of the prostate: transrectal hyperthermia. Smith’s
Textbook of Endourolgy. Eds: Smith A and Badlani GH. 1996.
14.
Kaplan SA: Prostatic endoprosthetics. In: Textbook of Endourology. Eds: Sosa E, Albala DM,
Jenkins AD, Perlmutter AP. WB Saunders, 1996.
15.
Te AE and Kaplan SA: Urodynamics in BPH. In: Textbook of Benign Prostatic Hyperplasia.
Eds: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. Isis Medical Media Ltd.,
Oxford, England. 1996.
16.
Te AE and Kaplan SA: Prostatic endoprosthetics. In: Textbook of Benign Prostatic Hyperplasia.
Eds: Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. Isis Medical Media Ltd,
Oxford, England. 1996.
17.
Gibbons RP, Altwein JE, Bruskewitz RC, Choquenet C, Costello AJ, Flam TA, Fourcade RO,
Koshiba K, McNicholas TA, Stein BS, Kaplan SA: Surgical and Laser Treatment. 3rd
International Consultation on Benign Prostatic Hyperplasia. ED: Cockett ATK, Khoury S, Aso
Chatelain C, Denis L, Griffiths K, Murphy G. SCI Ltd., 1996.
18.
Kaplan SA and Jacobs BZ: Urinary incontinence in patients with Parkinson’s Disease. In:
Parkinson’s Disease. Kuttscher, A. 1996
19.
Santarosa RP and Kaplan SA: Transurethral resection of the prostate. In: Operative Urology.
Eds: Krane RJ, Fitzpatrick J, Siroky MB. Churchill Livingstone, 1996.
20.
Te AE and Kaplan SA: Electrovaporization principles. In: Prostate Surgery. Ed: Narayan. 1997.
21.
Roehrborn CG, Andersen jT, Correa R, Di Silverio F, Kaplan SA, Kurth KH, Rubben H, Torp Pedersen ST, Watanabe H, Zerbib M: Initial diagnostic evaluation of men with lower urinary tract
symptoms. 3rd International Consultation on Benign Prostatic Hyperplasia. ED: Cockett ATK,
Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G. SCI Ltd., 1996.
22.
Santarosa RP, Te AE, Kaplan SA: Transurethral resection, incision and ablation of the prostate.
Glenn’s Urologic Surgery, 5th edition. Ed. Graham SD. 1997.
23.
Staiman VR and Kaplan SA: Bladder dysfunction. Lebovitz H. Ed., Therapy for Diabetes
Mellitus and Related Disorders. American Diabetes Association. page: 288, 1997.
24.
Te AE, Santarosa RP, Kaplan SA: Electrovaporization of the prostate: advanced application of
electrosurgical principles to the treatment of benign prostatic hyperplasia, In: Recent Advances in
Urology. ED: Kirby RS, O’Leary MP, Churchill Livingstone, 1998.
45
25.
Te AE and Kaplan SA: Complications of Minimally Invasive Surgery for BPH. In:
Complications in Urologic Surgery. Eds: Taneja, Smith & Ehrlich. 2000.
26.
Kohn I and Kaplan SA: Medical therapy of BPH. Atlas of Clinical Urology. Eds. Vaughan ED
and Perlmutter A. 2000.
27.
Kohn IJ and Kaplan SA: Lower urinary tract obstruction. In: Surgery. EDS: Carson CC, 2001.
28.
Kohn IJ, Te AE and Kaplan SA: Urodynamics of prostatitis. In: Textbook of prostatitis. EDS:
Nickel JC. 2000.
29.
Te AE, Ikeguchi EF, Choi J, Kaplan SA: Urodynamics and benign prostatic hyperplasia. In:
Textbook of benign prostatic hyperplasia. Eds: Kirby RS, McConnell JD, Fitzpatrick JM,
Roehrborn CG, Boyle P. Isis Medical Media Ltd., Oxford, England. 2000.
30.
Cabelin M, Te AE and Kaplan SA: Urogenital physiology. In: Rehabilitation Medicine. Ed:
Downey and Leiberman. 2000.
31.
Knowles D, Volpe M and Kaplan SA: Sexual dysfunction. In: Pelvic Disorders. Ed:Bourcier AP,
McGuire EJ and Abrams P. Harcourt Health Sciences (WB Saunders), Philadelphia, PA. 2001.
32.
Littlejohn JO, Kang YM, Kaplan SA: Transurethral vaporization of the prostate. In: Management
of Benign Prostatic Hypertrophy. ED: McVary KT. Humana Press. 2004
33.
Cooper KL, Kaplan SA: Overactive Bladder and Incontinence. In: Men’s Health volume 2. Eds:
Kirby RS, Carson C, Kirby MG, Farah RN. Martin Dunitz, London, 2003 (In Press, Fall 2003)
34.
Walmsley K, Gjersten CK, Kaplan SA: Medical management of BPH – an update. Campbell’s
Urology. Volume 2, Number 2, 2004.
ABSTRACTS (25 of 135)
1)
Kaplan SA, Chancellor MB, Blaivas JG: A urodynamic evluation of bladder and sphincter
behavior in patients with spinal cord lesions. J Urol 143:371A, 1990.
2)
Kaplan SA, Buttyan R, Olsson CA, Koo HP: SGP-2 Expression in diabetic rat bladders: evidence
of acute injury. 14th International Diabetes Federation Congress. June 1991.
3)
Kaplan SA: "Prostatic stents in the management of geriatric men with prostatism. Urodynamics
Society, May 1992.
4)
Te AE, Buttyan R, Koo HP, Olsson CA, Kaplan SA: Nerve growth factors in diabetic cystopathy.
International Continence Society. September 1992.
5)
Kaplan SA, Blaivas JG, Te AE: Urodynamic findings in patients with diabetic and voiding
symptoms: Surprising results. International Continence Society. September 1992.
6)
Kaplan SA, Olsson CA: Urodynamic evidence of vesical neck obstruction in men with chronic
prostatitis and the therapeutic role of TUIP. J. Urol., 149:406A, 1993.
46
7)
Kaplan SA: Alpha blockade: monotherapy for hypertension and BPH. 3rd International
Conference on BPH. Monte Carlo, June 1995.
8)
Kaplan SA, Santarosa RP and Te AE: The incidence of hypertension in men with benign prostatic
hyperplasia. XIIth European Urology Association, Paris, 1996.
9)
Kaplan SA: The ratio of transition zone to total prostate volume is higher in African - American
men than in their Caucasian or hispanic counterparts. XXIIth European Urology Association,
Paris, 1996.
10)
Kaplan SA, Laor E and Te AE: Transurethral rsection of the prostate (TURP) versus
electrovaporization of the prostate (VAP): a prospective, blinded comparative study of the
treatment of benign prostatic hyperplasia (BPH). XXIIth European Urology Association, Paris,
1996.
11)
Kaplan SA, Short K, Geller J et al: Baseline symptoms determine long-term symptomatic
response to finasteride: Results of a four-year, placebo-controlled trial. European Urology
Association, February, 1998, Barcelona, Spain.
12)
Kaplan SA for the NIH MTOPS Study Group: Medical therapy of prostate symptoms
(MTOPS): baseline urodynamic data and correlation with prostate volume and prostate specific
antigen (PSA). J Urol (159): 330, 1998.
13)
Kaplan SA, Blute M, Bruskewitz RC, Larson TR, Utz W, Ugarte R, Mayer R: Long term
efficacy and durability in 345 patients treated with transurethral microwave thermotherapy for
benign prostatic hyperplasia: Five year results. J Urol, 167 (4):1153, 2002.
14)
Kaplan SA and Te AE: Electrovaporization of the prostate utilizing the roller ball and / or
vaporizing loop for symptomatic benign prostatic hyperplasia (BPH): The 7 – year Columbia
experience in 650 consecutive men. J Urol, 167 (4):169, 1437, 2002.
15)
Kaplan SA and Te AE: Pressure / Flow evaluation of ethnically diverse men treated by
minimally invasive surgical therapies for BPH: The New York Presbyterian Hospital
experience. J Urol, 167 (4):1454, 2002.
16)
Kaplan SA, Roehrborn CG, McConnell JD: Baseline symptoms, uroflow, and post void
residual urine as predictors of BPH clinical progression in the medically treated arms of
MTOPS. J Urol, 169 (4): 1289, 2003.
17)
Kaplan SA, Olsson CA, Gross R, Kaufman D, Gameroff MJ, Weissman MM: Chromosome 13
syndrome: A pleiotropic genetic linkage between panic disorder and interstitial cystitis. J Urol
171 (4): 522, 2004.
18)
Kaplan SA, Walmsley K, Te AE: Use of muscarinic receptor antagonists as monotherapy in
men with lower urinary tract symptoms who failed previous therapy with alpha blockers. J Urol
171 (4): 917, 2004.
47
19)
Kaplan SA, Roehrborn C, Lee M, The Medical Therapy of Prostatic Symptoms (MTOPS)
Research Group: The superior beneficial effect of combination therapy with doxazosin and
finasteride versus either drug alone on clinical progression of benign prostatic hyperplasia in
the MTOPS trial was not dependent on patients having prostatic enlargement at baseline. Eur
Urol, 4(3): 841, 2005.
20)
Kaplan SA, Roehrborn CG, Lee MW, and the MTOPS Research Group: The superior
beneficial effect of combination therapy with doxazosin and finasteride versus either drug alone
on clinical progression of benign prostatic hyperplasia is not dependent on patients having
prostate enlargement at baseline: data from the medical therapy of prostatic symptoms
(MTOPS) trial. J Urol 173 (4): 443, 2005.
21)
Kaplan SA, Gonzalez R, Ogiste J, Te AE: Combination of an α1 – blocker, alfuzosin and a
PDE5
inhibitor, sildenafil citrate, is superior to monotherapy in treating lower urinary tract
symptoms
and sexual dysfunction. Eur Urol 592:197, 2006.
22)
Kaplan SA: The age related decline in testosterone is significantly exacerbated in obese men
with the metabolic syndrome: what are the implications of this for the relatively high incidence
of erectile dysfunction observed in these men? J Urol 175 (4): 692, 2006.
23)
Kaplan SA, Gonzalez RR, Ogiste J, Te AE: Combination of an alpha blocker, alfuzosin SR
and a PDE – 5 inhibitor, sildenafil citrate is uperior to monotherapy in treating lower urinary
tract symptoms (LUTS) and sexual dysfunction. J Urol 175 (4): 1638, 2006.
24)
Kaplan SA, Fisch H, Berriman SJ, Saini R, Lee R, Te AE: Central obesity as measured by
waist circumference is predictive of severity of lower urinary tract symptoms, sexual
dysfunction, and
components of the metabolic syndrome. J Urol, 177 (4): 1508, 2007.
25)
Kaplan SA, Wilson TH: Association between BPH and the metabolic syndrome in the Reduce
population. J Urol, 177 (4): 1548, 2007.
PRESENTATIONS
(25 of 375)
New York Surgical Society, December, 1984, New York, NY
"Small Bowel Transplantation in the Rat"
International Society of Analytical Cytology, August 1987 (Cambridge University, Great Britain)
"The Use of Mean Channel Number Versus Modal Channel Number in Flow Cytometric Analysis"
American Diabetes Association Annual Meeting, June 1991, Washington, D.C.
"SGP-2 Expression in Diabetic Rat Bladders"
Clinical Society of Genitourinary Surgeons, March, 1993, New York, NY
"Novel molecular approaches in bladder dysfunction"
1st Annual International Symposium of the Institute of Urology and Transplantation, Karachi, Pakistan,
March, 1994
"Future trends in the management of BPH"
48
"Finasteride in the treatment of BPH"
Visiting Professor, Universidade de Sao Paulo, Brazil, February, 1995
“Molecular staging of prostate cancer”
“New advances in the treatment of incontinence”
“Electrovaporization of the prostate”
3rd International Conference on BPH, Monte Carlo, June 1995
“Electrovaporization of the Prostate”
“Alpha blockade: monotherapy for hypertension and BPH”
“Doxazosin does not adversely affect blood pressure of physiologically or pharmacologically
normotensive patients with benign prostatic hyperplasia”
“Doxazosin in elderly men with BPH”
XX Brazilian Congress of Urology, Salvador, Bahia, November, 1995
“Finasteride in the management of BPH”
“Alpha Blockers in BPH”
“Electrovaporization of the Prostate”
“Management of stress urinary incontinence”
“The future of BPH”
American Urological Association Annual Meeting, Orlando, FL, May, 1996
Urodynamics Society
“New Surgical Alternatives for BPH - Results”
“Electrovaporization of the prostate for symptomatic benign prostatic hyperplasia: the 1 year experience”
Urodynamics Society Forum
“Results of non - pharmacologic therapy for BPH”
Program Chairman: “BPH - Where are we in 1996?”
“Minimally invasive alternative therapy for BPH”Plenary Session - Debate Moderator
“The place of urodynamics in the evaluation of the patient with BPH”
Plenary Session
“ The role of the Vaportrode in BPH”
British Urology Association, Bourrnmouth, United Kingdom, June, 1997
“BPH: the next millenium”
4th Annual BPH Consultation, World Health Organization, Paris, July, 1997
“Patient satisfaction with BPH therapy”
“Alpha blockade and sexual therapy”
“Electrovaporization”
Annual Meeting of the American Urological Association Meeting, Atlanta, 2000
“The role of 5 – alpha reductase inhibitors in the management of BPH (AUA Plenary Course)
49
Plenary presentation: “BPH highlights”
“Depression and female sexual function in women with urinary incontinence”
“Doxazosin for the treatment of concomitant hypertension and benign prostatic hyperplasia (BPH): an
open - label study in patients with well controlled hypertension”
“Combined long term results based on initial prostate size of U.S. multi - center studies using the
TARGIS system for benign prostatic hyperplasia”
“The efficacy and safety of finasteride in elderly men with benign prostatic hyperplasia”
Annual Japanese Urology Association Meeting, Tokyo, April, 2002
“Update on the treatment for stress urinary incontinence”
“Medical therapy for BPH”
Society of Urodynamics and Female Urology, Orlando, May, 2002
“Disappointing results with bone anchors for stress urinary incontinence”
American Urological Association Annual Meeting, Orlando, May, 2002
“Pharmacologic management of BPH”
“Disappointing long term results of transvaginal bone anchors in the treatment of stress urinary
incontinence (SUI): The 3 – year New York Presbyterian Hospital experience”
“Use of finasteride as a diagnostic tool in evaluating men with a serum PSA > 4 and previous negative
prostate biopsy”
“Urodynamic findings in men with DM and BPH”
“Long term efficacy and durability in 345 patients treated with transurethral microwave
thermotherapy for benign prostatic hyperplasia: Five year results”
“Electrovaporization of the prostate utilizing the roller ball and / or vaporizing loop for symptomatic
benign prostatic hyperplasia (BPH): The 7 – year Columbia experience in 650 consecutive men”
“Pressure / Flow evaluation of ethnically diverse men treated by minimally invasive surgical therapies
for BPH: The New York Presbyterian Hospital experience”
Visiting Professor, Department of Urology, Temple University, October, 2004
“Sex and BPH: Are they related?”
“Muscarinic receptor antagonists in men with BPH”
“Update on the AUA Guidelines for BPH”
Grand Rounds, Njmegen, Netherlands, June 12, 2006
“New insights into Male LUTS”
Visiting Professor, Duke University, Durham, July 17 – 18, 2006
50
“Male pelvic dysfunction: urologic call to arms”
Visiting Professor, Texas A & M, Temple, August 2, 2006
“Male pelvic dysfunction: urologic call to arms”
Prostate Disease”
New York Section, AUA Annual Meeting, India, November, 2006
“Anticholinergics in men”
“Sexual Dysfunction and BPH”
“ How I do urethral slings”
American Urologic Association Annual Meeting, Anaheim, May, 2007
“Evolution of treatment of LUTS” Course Chair
“Medical therapy for BPH” Course Chair
Course Director
“Male pelvic health”
Plenary Session
“Role of urodynamics in the evaluation of male LUTS”
“Central obesity as measured by waist circumference is predictive of severity of lower urinary tract
symptoms, sexual dysfunction, and components of the metabolic syndrome”
“Association between BPH and the metabolic syndrome in the Reduce population”
“Effects of tolterodine extended release and / or tamsulosin on bladder diary variables in men with
lower urinary tract symptoms including overactive bladder”
“Effects of tolterodine extended release and / or tamsulosin on international prostate symptoms
scores in men with lower urinary tract symptoms including overactive bladder”
NIDDK, Strategic Panel on Prostate Disease, Baltimore, July, 2007
Chair, Strategic Committee
Date:
Signature:
51

Date of Preparation: April 17, 2008 Department of Urology

Transcription

Similar documents